Form **990**

Department of the Treasury
Internal Revenue Service

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung benefit trust or private foundation)

▶ The organization may have to use a copy of this return to satisfy state reporting requirements.

OMB No. 1545-0047

2004

Open to Public Inspection

A **For the 2004 calendar year, or tax year beginning APRIL 1 , 2004, and ending MARCH 31 , 20 05**

B Check if applicable
- ☐ Address change
- ☐ Name change
- ☐ Initial return
- ☐ Final return
- ☐ Amended return
- ☐ Application pending

Please use IRS label or print or type. See Specific Instructions.

C Name of organization
MUSCULAR DYSTROPHY ASSOCIATION, INC.

Number and street (or P O box if mail is not delivered to street address) Room/suite
3300 EAST SUNRISE DRIVE

City or town, state or country, and ZIP + 4
TUCSON, ARIZONA 85718-3299

D Employer identification number
13 1665552

E Telephone number
(520) 529-2000

F Accounting method: ☐ Cash ☑ Accrual ☐ Other (specify) ▶

• **Section 501(c)(3) organizations and 4947(a)(1) nonexempt charitable trusts must attach a completed Schedule A (Form 990 or 990-EZ).**

H and I are not applicable to section 527 organizations.

H(a) Is this a group return for affiliates? ☐ Yes ☑ No

H(b) If "Yes," enter number of affiliates ▶

H(c) Are all affiliates included? ☐ Yes ☐ No (If "No," attach a list See instructions)

H(d) Is this a separate return filed by an organization covered by a group ruling? ☐ Yes ☑ No

G **Website:** ▶ **WWW.MDAUSA.ORG**

J **Organization type** (check only one) ▶ ☑ 501(c) (**3**) ◀ (insert no.) ☐ 4947(a)(1) or ☐ 527

K Check here ▶ ☐ if the organization's gross receipts are normally not more than $25,000 The organization need not file a return with the IRS, but if the organization received a Form 990 Package in the mail, it should file a return without financial data **Some states require a complete return.**

I Group Exemption Number ▶

L Gross receipts: Add lines 6b, 8b, 9b, and 10b to line 12 ▶ **330,540,449**

M Check ▶ ☑ if the organization is **not** required to attach Sch. B (Form 990, 990-EZ, or 990-PF)

Part I Revenue, Expenses, and Changes in Net Assets or Fund Balances (See page 18 of the instructions.)

Revenue	1	Contributions, gifts, grants, and similar amounts received:			
	a	Direct public support	1a	172,184,964	
	b	Indirect public support	1b	874,071	
	c	Government contributions (grants)	1c		
	d	**Total** (add lines 1a through 1c) (cash $ 173,059,035 noncash $ 0)			1d 173,059,035
	2	Program service revenue including government fees and contracts (from Part VII, line 93)			2
	3	Membership dues and assessments			3
	4	Interest on savings and temporary cash investments			4
	5	Dividends and interest from securities			5 3,762,527
	6a	Gross rents	6a		
	b	Less: rental expenses	6b		
	c	Net rental income or (loss) (subtract line 6b from line 6a)			6c
	7	Other investment income (describe ▶ LOSS ON RESTRICTED SECURITIES)			7 (82,075)
	8a	Gross amount from sales of assets other than inventory	(A) Securities 123,082,059	(B) Other	
	b	Less: cost or other basis and sales expenses	113,937,731	8b	
	c	Gain or (loss) (attach schedule) EXHIBIT A	9,114,328	8c	
	d	Net gain or (loss) (combine line 8c, columns (A) and (B))			8d 9,144,328
	9	Special events and activities (attach schedule). If any amount is from **gaming**, check here ▶ ☐			
	a	Gross revenue (not including $ 145,862,463 of EXHIBIT B contributions reported on line 1a)	9a 30,154,258		
	b	Less: direct expenses other than fundraising expenses	9b 30,154,258		
	c	Net income or (loss) from special events (subtract line 9b from line 9a)			9c 0
	10a	Gross sales of inventory, less returns and allowances	10a		
	b	Less: cost of goods sold	10b		
	c	Gross profit or (loss) from sales of inventory (attach schedule) (subtract line 10b from line 10a)			10c
	11	Other revenue (from Part VII, line 103)			11 564,645
	12	**Total revenue** (add lines 1d, 2, 3, 4, 5, 6c, 7, 8d, 9c, 10c, and 11)			12 186,448,460
Expenses	13	Program services (from line 44, column (B))			13 134,321,766
	14	Management and general (from line 44, column (C))			14 12,817,861
	15	Fundraising (from line 44, column (D))			15 28,574,306
	16	Payments to affiliates (attach schedule)			16
	17	**Total expenses** (add lines 16 and 44, column (A))			17 175,713,933
Net Assets	18	Excess or (deficit) for the year (subtract line 17 from line 12)			18 10,734,527
	19	Net assets or fund balances at beginning of year (from line 73, column (A))			19 162,764,113
	20	Other changes in net assets or fund balances (attach explanation) Exhibit N			20 (12,540,593)
	21	Net assets or fund balances at end of year (combine lines 18, 19, and 20)			21 160,958,047

For Privacy Act and Paperwork Reduction Act Notice, see the separate instructions. Cat No. 11282Y Form **990** (2004)

SCANNED OCT 20 2005

RECEIVED
OCT 04 2005
OGDEN, UT

GB 3

Part II Statement of Functional Expenses All organizations must complete column (A). Columns (B), (C), and (D) are required for section 501(c)(3) and (4) organizations and section 4947(a)(1) nonexempt charitable trusts but optional for others (See page 22 of the instructions.)

	Do not include amounts reported on line 6b, 8b, 9b, 10b, or 16 of Part I.		(A) Total	(B) Program services	(C) Management and general	(D) Fundraising
Exhibit C	22 Grants and allocations (attach schedule) (cash $ 30,567,845 noncash $ 0)	22	30,567,845	30,567,845		
Exhibit K	23 Specific assistance to individuals (attach schedule)	23	16,479,805	16,479,805		
	24 Benefits paid to or for members (attach schedule)	24				
	25 Compensation of officers, directors, etc.	25				
	26 Other salaries and wages	26	54,557,492	46,709,064	5,333,134	2,515,294
	27 Pension plan contributions	27	3,514,397	3,070,267	286,077	158,053
	28 Other employee benefits	28	8,151,514	7,121,367	663,548	366,599
	29 Payroll taxes	29	4,583,845	3,983,053	384,414	216,378
	30 Professional fundraising fees	30				
	31 Accounting fees	31	141,461	0	141,461	0
	32 Legal fees	32	146,204	0	146,204	0
	33 Supplies	33	2,582,749	2,034,468	126,023	422,258
	34 Telephone	34	4,818,436	2,480,339	344,052	1,994,045
	35 Postage and shipping	35	8,056,248	2,228,300	722,196	5,105,752
	36 Occupancy	36	9,185,107	7,948,103	549,831	687,173
	37 Equipment rental and maintenance	37				
	38 Printing and publications	38	5,902,161	2,250,377	626,854	3,024,930
	39 Travel	39	6,203,559	5,278,462	412,058	513,039
	40 Conferences, conventions, and meetings	40				
	41 Interest	41				
Exhibit D	42 Depreciation, depletion, etc. (attach schedule)	42	1,522,756	891,978	577,801	52,977
	43 Other expenses not covered above (itemize): a	43a				
	b MISCELLANEOUS	43b	4,577,697	1,470,274	2,308,659	798,764
	c CONTRACT SERVICES &	43c				
	d PROFESSIONAL FEES	43d	14,722,657	1,808,064	195,549	12,719,044
	e	43e				
	44 Total functional expenses (add lines 22 through 43). *Organizations completing columns (B)-(D), carry these totals to lines 13–15*	44	175,713,933	134,321,766	12,817,861	28,574,306

Joint Costs. Check ▶ ☑ if you are following SOP 98-2.

Are any joint costs from a combined educational campaign and fundraising solicitation reported in (B) Program services? ▶ ☑ Yes ☐ No

If "Yes," enter (i) the aggregate amount of these joint costs $ 4,390,456 ; (ii) the amount allocated to Program services $ 1,361,041 ; (iii) the amount allocated to Management and general $ 834,187 ; and (iv) the amount allocated to Fundraising $ 2,195,228

Part III Statement of Program Service Accomplishments (See page 25 of the instructions.)

What is the organization's primary exempt purpose? ▶ research/patient & community services/professional education

All organizations must describe their exempt purpose achievements in a clear and concise manner. State the number of clients served, publications issued, etc. Discuss achievements that are not measurable. (Section 501(c)(3) and (4) organizations and 4947(a)(1) nonexempt charitable trusts must also enter the amount of grants and allocations to others.)

		Program Service Expenses (Required for 501(c)(3) and (4) orgs., and 4947(a)(1) trusts, but optional for others.)
a	**RESEARCH - EXHIBIT H, PART III a** (Grants and allocations $ 30,567,845)	34,291,741
b	**PATIENT & COMMUNITY SERVICES - EXHIBIT H, PART III b** (Grants and allocations $)	79,231,125
c	**PROFESSIONAL & PUBLIC HEALTH EDUCATION - EXHIBIT H, PART III c** (Grants and allocations $)	20,798,900
d	(Grants and allocations $)	
e	Other program services (attach schedule) (Grants and allocations $)	
f	**Total of Program Service Expenses** (should equal line 44, column (B), Program services) ▶	134,321,766

Part IV Balance Sheets (See page 25 of the instructions.)

	Note: *Where required, attached schedules and amounts within the description column should be for end-of-year amounts only*			(A) Beginning of year		(B) End of year
Assets	45 Cash—non-interest-bearing			798,889	45	5,552,040
	46 Savings and temporary cash investments			15,645,315	46	9,683,450
	47a Accounts receivable	47a	5,237,619			
	b Less: allowance for doubtful accounts	47b	0	5,531,419	47c	5,237,619
	48a Pledges receivable	48a	10,319,308			
	b Less: allowance for doubtful accounts	48b	0	12,486,762	48c	10,319,308
	49 Grants receivable				49	
	50 Receivables from officers, directors, trustees, and key employees (attach schedule)				50	
	51a Other notes and loans receivable (attach schedule)	51a				
	b Less: allowance for doubtful accounts	51b			51c	
	52 Inventories for sale or use				52	
	53 Prepaid expenses and deferred charges			2,030,507	53	3,321,602
Exhibit F	54 Investments—securities (attach schedule) ▶ ☐ Cost ☑ FMV			79,179,318	54	83,400,470
	55a Investments—land, buildings, and equipment: basis	55a				
	b Less: accumulated depreciation (attach schedule)	55b			55c	
Exhibit F	56 Investments—other (attach schedule)			77,403,635	56	87,166,757
	57a Land, buildings, and equipment: basis	57a	16,906,940			
Exhibit D	b Less: accumulated depreciation (attach schedule)	57b	6,390,018	10,545,733	57c	10,516,922
	58 Other assets (describe ▶)				58	
	59 **Total assets** (add lines 45 through 58) (must equal line 74)			203,621,578	59	215,198,168
Liabilities	60 Accounts payable and accrued expenses			19,625,347	60	30,143,971
	61 Grants payable			21,232,118	61	24,096,150
	62 Deferred revenue				62	
	63 Loans from officers, directors, trustees, and key employees (attach schedule)				63	
	64a Tax-exempt bond liabilities (attach schedule)				64a	
	b Mortgages and other notes payable (attach schedule)				64b	
	65 Other liabilities (describe ▶)				65	
	66 **Total liabilities** (add lines 60 through 65)			40,857,465	66	54,240,121
Net Assets or Fund Balances	**Organizations that follow SFAS 117, check here** ▶ ☑ and complete lines 67 through 69 and lines 73 and 74.					
	67 Unrestricted			162,764,113	67	160,958,047
	68 Temporarily restricted				68	
	69 Permanently restricted				69	
	Organizations that do not follow SFAS 117, check here ▶ ☐ and complete lines 70 through 74.					
	70 Capital stock, trust principal, or current funds				70	
	71 Paid-in or capital surplus, or land, building, and equipment fund				71	
	72 Retained earnings, endowment, accumulated income, or other funds				72	
	73 **Total net assets or fund balances** (add lines 67 through 69 **or** lines 70 through 72; column (A) **must** equal line 19; column (B) **must** equal line 21)			162,764,113	73	160,958,047
	74 **Total liabilities and net assets / fund balances** (add lines 66 and 73)			203,621,578	74	215,198,168

Form 990 is available for public inspection and, for some people, serves as the primary or sole source of information about a particular organization. How the public perceives an organization in such cases may be determined by the information presented on its return. Therefore, please make sure the return is complete and accurate and fully describes, in Part III, the organization's programs and accomplishments.

Part IV-A **Reconciliation of Revenue per Audited Financial Statements with Revenue per Return** (See page 27 of the instructions.)

a	Total revenue, gains, and other support per audited financial statements ▶	a	182,940,829
b	Amounts included on line a but not on line 12, Form 990:		
(1)	Net unrealized gains on investments . $ (3,507,631)		
(2)	Donated services and use of facilities $		
(3)	Recoveries of prior year grants . . . $		
(4)	Other (specify): .... $		
	Add amounts on lines (1) through (4) ▶	b	(3,507,631)
c	Line a minus line b . . . . . ▶	c	186,448,460
d	Amounts included on line 12, Form 990 but not on line a:		
(1)	Investment expenses not included on line 6b, Form 990. . . $		
(2)	Other (specify): .... $		
	Add amounts on lines (1) and (2) ▶	d	0
e	Total revenue per line 12, Form 990 (line c plus line d) . . . . . ▶	e	186,448,460

Part IV-B **Reconciliation of Expenses per Audited Financial Statements with Expenses per Return**

a	Total expenses and losses per audited financial statements . . ▶	a	175,713,933
b	Amounts included on line a but not on line 17, Form 990:		
(1)	Donated services and use of facilities $		
(2)	Prior year adjustments reported on line 20, Form 990. . . . $		
(3)	Losses reported on line 20, Form 990 $		
(4)	Other (specify): .... $		
	Add amounts on lines (1) through (4) ▶	b	0
c	Line a minus line b . . . . . ▶	c	175,713,933
d	Amounts included on line 17, Form 990 but not on line a:		
(1)	Investment expenses not included on line 6b, Form 990 . . $		
(2)	Other (specify): .... $		
	Add amounts on lines (1) and (2) ▶	d	0
e	Total expenses per line 17, Form 990 (line c plus line d) . . . . . ▶	e	175,713,933

Part V **List of Officers, Directors, Trustees, and Key Employees** (List each one even if not compensated; see page 27 of the instructions.)

(A) Name and address	(B) Title and average hours per week devoted to position	(C) Compensation (If not paid, enter -0-.)	(D) Contributions to employee benefit plans & deferred compensation	(E) Expense account and other allowances
ROBERT ROSS (KEY EMPLOYEE) 3300 EAST SUNRISE DRIVE, TUCSON AZ 85718	President & CEO 100%	365,000	34,321	0
EXHIBIT I FOR LISTING OF OFFICERS AND MEMBERS OF THE BOARD OF DIRECTORS WHO SERVE WITHOUT COMPENSATION	AS NEEDED	0	0	0

75 Did any officer, director, trustee, or key employee receive aggregate compensation of more than $100,000 from your organization and all related organizations, of which more than $10,000 was provided by the related organizations? ▶ ☐ Yes ☑ No

If "Yes," attach schedule—see page 28 of the instructions.

Part VI Other Information (See page 28 of the instructions.)

			Yes	No
76	Did the organization engage in any activity not previously reported to the IRS? If "Yes," attach a detailed description of each activity	76		✔
77	Were any changes made in the organizing or governing documents but not reported to the IRS? If "Yes," attach a conformed copy of the changes.	77		✔
78a	Did the organization have unrelated business gross income of $1,000 or more during the year covered by this return?	78a	✔	
b	If "Yes," has it filed a tax return on **Form 990-T** for this year?	78b	✔	
79	Was there a liquidation, dissolution, termination, or substantial contraction during the year? If "Yes," attach a statement	79		✔
80a	Is the organization related (other than by association with a statewide or nationwide organization) through common membership, governing bodies, trustees, officers, etc., to any other exempt or nonexempt organization?	80a		✔
b	If "Yes," enter the name of the organization ▶ ..... and check whether it is ☐ exempt **or** ☐ nonexempt.			
81a	Enter direct and indirect political expenditures. See line 81 instructions — 81a: **NONE**			
b	Did the organization file **Form 1120-POL** for this year?	81b		✔
82a	Did the organization receive donated services or the use of materials, equipment, or facilities at no charge or at substantially less than fair rental value?	82a	✔	
b	If "Yes," you may indicate the value of these items here. Do not include this amount as revenue in Part I or as an expense in Part II. (See instructions in Part III.) — 82b			
83a	Did the organization comply with the public inspection requirements for returns and exemption applications?	83a	✔	
b	Did the organization comply with the disclosure requirements relating to quid pro quo contributions?	83b	✔	
84a	Did the organization solicit any contributions or gifts that were not tax deductible?	84a	✔	
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?	84b	✔	
85	*501(c)(4), (5), or (6) organizations.* **a** Were substantially all dues nondeductible by members?	85a		
b	Did the organization make only in-house lobbying expenditures of $2,000 or less?	85b		
	If "Yes" was answered to either 85a or 85b, **do not** complete 85c through 85h below unless the organization received a waiver for proxy tax owed for the prior year.			
c	Dues, assessments, and similar amounts from members — 85c			
d	Section 162(e) lobbying and political expenditures — 85d			
e	Aggregate nondeductible amount of section 6033(e)(1)(A) dues notices — 85e			
f	Taxable amount of lobbying and political expenditures (line 85d less 85e) — 85f			
g	Does the organization elect to pay the section 6033(e) tax on the amount on line 85f?	85g		
h	If section 6033(e)(1)(A) dues notices were sent, does the organization agree to add the amount on line 85f to its reasonable estimate of dues allocable to nondeductible lobbying and political expenditures for the following tax year?	85h		
86	*501(c)(7) orgs.* Enter: **a** Initiation fees and capital contributions included on line 12 — 86a			
b	Gross receipts, included on line 12, for public use of club facilities — 86b			
87	*501(c)(12) orgs.* Enter: **a** Gross income from members or shareholders — 87a			
b	Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.) — 87b			
88	At any time during the year, did the organization own a 50% or greater interest in a taxable corporation or partnership, or an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? If "Yes," complete Part IX	88		✔
89a	*501(c)(3) organizations.* Enter: Amount of tax imposed on the organization during the year under: section 4911 ▶ **NONE** ; section 4912 ▶ **NONE** ; section 4955 ▶ **NONE**			
b	*501(c)(3) and 501(c)(4) orgs.* Did the organization engage in any section 4958 excess benefit transaction during the year or did it become aware of an excess benefit transaction from a prior year? If "Yes," attach a statement explaining each transaction	89b		✔
c	Enter: Amount of tax imposed on the organization managers or disqualified persons during the year under sections 4912, 4955, and 4958 ▶ **0**			
d	Enter: Amount of tax on line 89c, above, reimbursed by the organization ▶ **0**			
90a	List the states with which a copy of this return is filed ▶ **EXHIBIT G**			
b	Number of employees employed in the pay period that includes March 12, 2004 (See instructions.) — 90b: **1,335**			
91	The books are in care of ▶ **DANIEL BERECK, DIRECTOR OF FINANCE** Telephone no. ▶ **(520) 529-2000** Located at ▶ **3300 EAST SUNRISE DRIVE, TUCSON ARIZONA** ZIP + 4 ▶ **85718-3299**			
92	*Section 4947(a)(1) nonexempt charitable trusts filing Form 990 in lieu of* ***Form 1041***—Check here ▶ ☐ and enter the amount of tax-exempt interest received or accrued during the tax year ▶ 92			

Part VII Analysis of Income-Producing Activities (See page 33 of the instructions.)

Note: *Enter gross amounts unless otherwise indicated.*	Unrelated business income		Excluded by section 512, 513, or 514		(E) Related or exempt function income
	(A) Business code	(B) Amount	(C) Exclusion code	(D) Amount	
93 Program service revenue:					
a					
b					
c					
d					
e					
f Medicare/Medicaid payments					
g Fees and contracts from government agencies					
94 Membership dues and assessments					
95 Interest on savings and temporary cash investments			14	3,762,527	
96 Dividends and interest from securities					
97 Net rental income or (loss) from real estate:					
a debt-financed property					
b not debt-financed property					
98 Net rental income or (loss) from personal property					
99 Other investment income			18	(82,075)	
100 Gain or (loss) from sales of assets other than inventory			18	9,144,328	
101 Net income or (loss) from special events					
102 Gross profit or (loss) from sales of inventory					
103 Other revenue: a LIST RENTALS			13	144,566	
b ADVERTISING-PATIENT PUBLICATION	541800	349,651			
c ROYALTY INCOME			15	69,597	
d GREETING CARD INCOME					831
e					
104 Subtotal (add columns (B), (D), and (E))		349,651		13,038,943	831
105 **Total** (add line 104, columns (B), (D), and (E)) ▶					13,389,425

Note: *Line 105 plus line 1d, Part I, should equal the amount on line 12, Part I.*

Part VIII Relationship of Activities to the Accomplishment of Exempt Purposes (See page 34 of the instructions.)

Line No. ▼	Explain how each activity for which income is reported in column (E) of Part VII contributed importantly to the accomplishment of the organization's exempt purposes (other than by providing funds for such purposes)
103d	SALES OF GREETING CARDS FEATURING PRINTED REPRODUCTIONS OF ORGINAL ARTWORK BY ARTIST WITH DISABILITIES IMPOSED BY NEUROMUSCULAR DISEASES IN MDA'S PROGRAMS, CONTRIBUTES IMPORTANTLY TO THE ACHIEVEMENT OF THE ASSOCIATION'S EDUCATIONAL PURPOSES BY ENHANCING PUBLIC AWARENESS THAT CREATIVITY TRANSCENDS DISABILITY.

Part IX Information Regarding Taxable Subsidiaries and Disregarded Entities (See page 34 of the instructions.)

(A) Name, address, and EIN of corporation, partnership, or disregarded entity	(B) Percentage of ownership interest	(C) Nature of activities	(D) Total income	(E) End-of-year assets
	%			
	%			
	%			
	%			

Part X Information Regarding Transfers Associated with Personal Benefit Contracts (See page 34 of the instructions.)

(a) Did the organization, during the year, receive any funds, directly or indirec[illegible] ☐ Yes ☑ No

(b) Did the organization, during the year, pay premiums, direc[illegible]

Note: *If "Yes" to (b), file Form 8870 and Form 4720 (see inst[illegible]*

Please Sign Here

Under penalties of perjury, I declare that I have examined this return, and belief, it is true, correct, and complete. Declaration of preparer

Signature of officer

DANIEL BERECK, ASSISTANT TREASURER

Type or print name and title

Paid Preparer's Use Only

Preparer's signature

Firm's name (or yours if self-employed), address, and ZIP + 4

[redacted]

SCHEDULE A (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Organization Exempt Under Section 501(c)(3)

(Except Private Foundation) and Section 501(e), 501(f), 501(k), 501(n), or Section 4947(a)(1) Nonexempt Charitable Trust

Supplementary Information—(See separate instructions.)

▶ **MUST be completed by the above organizations and attached to their Form 990 or 990-EZ**

OMB No. 1545-0047

2004

Name of the organization
MUSCULAR DYSTROPHY ASSOCIATION, INC

Employer identification number
13 1665552

Part I Compensation of the Five Highest Paid Employees Other Than Officers, Directors, and Trustees

(See page 1 of the instructions. List each one. If there are none, enter "None.")

(a) Name and address of each employee paid more than $50,000	(b) Title and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans & deferred compensation	(e) Expense account and other allowances
GERALD C. WEINBERG TUCSON, ARIZONA	DIRECTOR OF FIELD ORGANIZATION, 100%	290,000	28,102	0
GAIL SCHMERTZ KERNER ESQ TUCSON, ARIZONA	GENERAL COUNSEL, 100%	190,000	24,858	0
DANIEL BERECK TUCSON, ARIZONA	DIRECTOR OF FINANCE, 100%	150,000	21,776	0
DAVID EPPIHIMER TUCSON, ARIZONA	VICE PRESIDENT WESTERN DIV. 100%	145,000	21,776	0
VALERIE A. CWIK, M.D. TUCSON, ARIZONA	MEDICAL DIRECTOR 100%	145,000	16,437	0
Total number of other employees paid over $50,000 ▶	253			

Part II Compensation of the Five Highest Paid Independent Contractors for Professional Services

(See page 2 of the instructions. List each one (whether individuals or firms). If there are none, enter "None.")

(a) Name and address of each independent contractor paid more than $50,000	(b) Type of service	(c) Compensation
THE SEGAL COMPANY NEW YORK, NEW YORK	BENEFITS CONSULTING SERVICES	333,613
LEE MILLER PRODUCTIONS INC LOS ANGELES, CALIFORNIA	TELEVISION PRODUCTION	164,500
ERNST & YOUNG LLP PHOENIX, ARIZONA	ACCOUNTANTS	141,461
ADP SCREENING AND SELECTION SERVICES. CHICAGO, ILLINOIS	EMPLOYMENT SCREENING SERVICE	61,816
ADP, INC CAROL STREAM, ILLINOIS	PAYROLL SERVICE	56,667
Total number of others receiving over $50,000 for professional services ▶ 0		

Part III Statements About Activities (See page 2 of the instructions.)

			Yes	No
1	During the year, has the organization attempted to influence national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum? If "Yes," enter the total expenses paid or incurred in connection with the lobbying activities ▶ $ _____ (Must equal amounts on line 38, Part VI-A, or line i of Part VI-B.)	1		✔
	Organizations that made an election under section 501(h) by filing Form 5768 must complete Part VI-A. Other organizations checking "Yes" must complete Part VI-B AND attach a statement giving a detailed description of the lobbying activities.			
2	During the year, has the organization, either directly or indirectly, engaged in any of the following acts with any substantial contributors, trustees, directors, officers, creators, key employees, or members of their families, or with any taxable organization with which any such person is affiliated as an officer, director, trustee, majority owner, or principal beneficiary? *(If the answer to any question is "Yes," attach a detailed statement explaining the transactions.)*			
a	Sale, exchange, or leasing of property?	2a		✔
b	Lending of money or other extension of credit?	2b		✔
c	Furnishing of goods, services, or facilities?	2c		✔
d	Payment of compensation (or payment or reimbursement of expenses if more than $1,000)? PART V FORM 990 & EXHIBIT M	2d	✔	
e	Transfer of any part of its income or assets?	2e		✔
3a	Do you make grants for scholarships, fellowships, student loans, etc.? (If "Yes," attach an explanation of how you determine that recipients qualify to receive payments.) SEE EXHIBIT J	3a	✔	
b	Do you have a section 403(b) annuity plan for your employees?	3b	✔	
4a	Did you maintain any separate account for participating donors where donors have the right to provide advice on the use or distribution of funds?	4a		✔
b	Do you provide credit counseling, debt management, credit repair, or debt negotiation services?	4b		✔

Part IV Reason for Non-Private Foundation Status (See pages 3 through 6 of the instructions.)

The organization is not a private foundation because it is: (Please check only **ONE** applicable box.)

5 ☐ A church, convention of churches, or association of churches. Section 170(b)(1)(A)(i).

6 ☐ A school. Section 170(b)(1)(A)(ii). (Also complete Part V.)

7 ☐ A hospital or a cooperative hospital service organization. Section 170(b)(1)(A)(iii).

8 ☐ A Federal, state, or local government or governmental unit. Section 170(b)(1)(A)(v).

9 ☐ A medical research organization operated in conjunction with a hospital. Section 170(b)(1)(A)(iii). **Enter the hospital's name, city, and state** ▶ .....

10 ☐ An organization operated for the benefit of a college or university owned or operated by a governmental unit. Section 170(b)(1)(A)(iv). (Also complete the **Support Schedule** in Part IV-A.)

11a ☑ An organization that normally receives a substantial part of its support from a governmental unit or from the general public. Section 170(b)(1)(A)(vi). (Also complete the **Support Schedule** in Part IV-A.)

11b ☐ A community trust. Section 170(b)(1)(A)(vi). (Also complete the **Support Schedule** in Part IV-A.)

12 ☐ An organization that normally receives: **(1) more than 33⅓%** of its support from contributions, membership fees, and gross receipts from activities related to its charitable, etc., functions—subject to certain exceptions, and **(2) no more than 33⅓%** of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Also complete the **Support Schedule** in Part IV-A.)

13 ☐ An organization that is not controlled by any disqualified persons (other than foundation managers) and supports organizations described in: **(1)** lines 5 through 12 above; or **(2)** section 501(c)(4), (5), or (6), if they meet the test of section 509(a)(2). (See section 509(a)(3).)

Provide the following information about the supported organizations. (See page 5 of the instructions.)

(a) Name(s) of supported organization(s)	**(b)** Line number from above

14 ☐ An organization organized and operated to test for public safety. Section 509(a)(4). (See page 5 of the instructions.)

Part IV-A Support Schedule (Complete only if you checked a box on line 10, 11, or 12.) ***Use cash method of accounting.***

Note: *You may use the worksheet in the instructions for converting from the accrual to the cash method of accounting.*

Calendar year (or fiscal year beginning in) ▶	(a) 2003	(b) 2002	(c) 2001	(d) 2000	(e) Total
15 Gifts, grants, and contributions received. (Do not include unusual grants. See line 28.)	176,254,772	167,334,500	152,734,601	144,842,611	641,166,484
16 Membership fees received					
17 Gross receipts from admissions, merchandise sold or services performed, or furnishing of facilities in any activity that is related to the organization's charitable, etc., purpose					
18 Gross income from interest, dividends, amounts received from payments on securities loans (section 512(a)(5)), rents, royalties, and unrelated business taxable income (less section 511 taxes) from businesses acquired by the organization after June 30, 1975	16,883,930	(4,778,299)	8,724,173	7,606,160	28,435,964
19 Net income from unrelated business activities not included in line 18.					
20 Tax revenues levied for the organization's benefit and either paid to it or expended on its behalf					
21 The value of services or facilities furnished to the organization by a governmental unit without charge. Do not include the value of services or facilities generally furnished to the public without charge					
22 Other income. Attach a schedule. Do not include gain or (loss) from sale of capital assets					
23 Total of lines 15 through 22	193,138,702	162,556,201	161,458,774	152,448,771	669,602,448
24 Line 23 minus line 17	193,138,702	162,556,201	161,458,774	152,448,771	669,602,448
25 Enter 1% of line 23	1,931,387	1,625,562	1,614,588	1,524,488	

26 Organizations described on lines 10 or 11:	**a** Enter 2% of amount in column (e), line 24 ▶	26a	13,392,049
b	Prepare a list for your records to show the name of and amount contributed by each person (other than a governmental unit or publicly supported organization) whose total gifts for 2000 through 2003 exceeded the amount shown in line 26a. **Do not file this list with your return.** Enter the total of all these excess amounts ▶	26b	0
c	Total support for section 509(a)(1) test: Enter line 24, column (e) ▶	26c	669,602,448
d	Add: Amounts from column (e) for lines: 18 28,435,964 19 ____ 22 ____ 26b ____ ▶	26d	28,435,964
e	Public support (line 26c minus line 26d total) ▶	26e	641,166,484
f	**Public support percentage (line 26e (numerator) divided by line 26c (denominator))** ▶	26f	96 %

27 Organizations described on line 12: **a** For amounts included in lines 15, 16, and 17 that were received from a "disqualified person," prepare a list for your records to show the name of, and total amounts received in each year from, each "disqualified person." **Do not file this list with your return.** Enter the sum of such amounts for each year:

(2003) ..... (2002) ..... (2001) ..... (2000) .....

b For any amount included in line 17 that was received from each person (other than "disqualified persons"), prepare a list for your records to show the name of, and amount received for each year, that was more than the **larger** of **(1)** the amount on line 25 for the year or **(2)** $5,000. (Include in the list organizations described in lines 5 through 11, as well as individuals.) **Do not file this list with your return.** After computing the difference between the amount received and the larger amount described in **(1)** or **(2),** enter the sum of these differences (the excess amounts) for each year.

(2003) ..... (2002) ..... (2001) ..... (2000) .....

c	Add: Amounts from column (e) for lines: 15 ____ 16 ____ 17 ____ 20 ____ 21 ____ ▶	27c	
d	Add: Line 27a total, ____ and line 27b total ____ ▶	27d	
e	Public support (line 27c total minus line 27d total) ▶	27e	
f	Total support for section 509(a)(2) test: Enter amount from line 23, column (e) ▶ 27f		
g	**Public support percentage (line 27e (numerator) divided by line 27f (denominator))** ▶	27g	%
h	**Investment income percentage (line 18, column (e) (numerator) divided by line 27f (denominator))** ▶	27h	%

28 Unusual Grants: For an organization described in line 10, 11, or 12 that received any unusual grants during 2000 through 2003, prepare a list for your records to show, for each year, the name of the contributor, the date and amount of the grant, and a brief description of the nature of the grant. **Do not file this list with your return.** Do not include these grants in line 15.

Part V **Private School Questionnaire** (See page 7 of the instructions.)
(To be completed ONLY by schools that checked the box on line 6 in Part IV)

			Yes	No
29	Does the organization have a racially nondiscriminatory policy toward students by statement in its charter, bylaws, other governing instrument, or in a resolution of its governing body?	29		
30	Does the organization include a statement of its racially nondiscriminatory policy toward students in all its brochures, catalogues, and other written communications with the public dealing with student admissions, programs, and scholarships?	30		
31	Has the organization publicized its racially nondiscriminatory policy through newspaper or broadcast media during the period of solicitation for students, or during the registration period if it has no solicitation program, in a way that makes the policy known to all parts of the general community it serves?	31		
	If "Yes," please describe; if "No," please explain (If you need more space, attach a separate statement.)			
32	Does the organization maintain the following:			
a	Records indicating the racial composition of the student body, faculty, and administrative staff?	32a		
b	Records documenting that scholarships and other financial assistance are awarded on a racially nondiscriminatory basis?	32b		
c	Copies of all catalogues, brochures, announcements, and other written communications to the public dealing with student admissions, programs, and scholarships?	32c		
d	Copies of all material used by the organization or on its behalf to solicit contributions?	32d		
	If you answered "No" to any of the above, please explain. (If you need more space, attach a separate statement.)			
33	Does the organization discriminate by race in any way with respect to:			
a	Students' rights or privileges?	33a		
b	Admissions policies?	33b		
c	Employment of faculty or administrative staff?	33c		
d	Scholarships or other financial assistance?	33d		
e	Educational policies?	33e		
f	Use of facilities?	33f		
g	Athletic programs?	33g		
h	Other extracurricular activities?	33h		
	If you answered "Yes" to any of the above, please explain. (If you need more space, attach a separate statement.)			
34a	Does the organization receive any financial aid or assistance from a governmental agency?	34a		
b	Has the organization's right to such aid ever been revoked or suspended?	34b		
	If you answered "Yes" to either 34a or b, please explain using an attached statement.			
35	Does the organization certify that it has complied with the applicable requirements of sections 4.01 through 4.05 of Rev. Proc. 75-50, 1975-2 C.B. 587, covering racial nondiscrimination? If "No," attach an explanation	35		

Part VI-A **Lobbying Expenditures by Electing Public Charities** (See page 9 of the instructions.)
(To be completed **ONLY** by an eligible organization that filed Form 5768)

Check ▶ **a** ☐ if the organization belongs to an affiliated group. Check ▶ **b** ☐ if you checked "a" and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Affiliated group totals	(b) To be completed for ALL electing organizations
36 Total lobbying expenditures to influence public opinion (grassroots lobbying)	36		
37 Total lobbying expenditures to influence a legislative body (direct lobbying)	37		
38 Total lobbying expenditures (add lines 36 and 37)	38		
39 Other exempt purpose expenditures	39		
40 Total exempt purpose expenditures (add lines 38 and 39)	40		
41 Lobbying nontaxable amount. Enter the amount from the following table—			
If the amount on line 40 is— / **The lobbying nontaxable amount is—**			
Not over $500,000 / 20% of the amount on line 40	41		
Over $500,000 but not over $1,000,000 / $100,000 plus 15% of the excess over $500,000			
Over $1,000,000 but not over $1,500,000 / $175,000 plus 10% of the excess over $1,000,000			
Over $1,500,000 but not over $17,000,000 / $225,000 plus 5% of the excess over $1,500,000			
Over $17,000,000 / $1,000,000			
42 Grassroots nontaxable amount (enter 25% of line 41)	42		
43 Subtract line 42 from line 36. Enter -0- if line 42 is more than line 36	43		
44 Subtract line 41 from line 38. Enter -0- if line 41 is more than line 38	44		
Caution: *If there is an amount on either line 43 or line 44, you must file Form 4720.*			

4-Year Averaging Period Under Section 501(h)

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the instructions for lines 45 through 50 on page 11 of the instructions.)

	Lobbying Expenditures During 4-Year Averaging Period				
Calendar year (or fiscal year beginning in) ▶	**(a)** 2004	**(b)** 2003	**(c)** 2002	**(d)** 2001	**(e)** Total
45 Lobbying nontaxable amount					
46 Lobbying ceiling amount (150% of line 45(e))					
47 Total lobbying expenditures					
48 Grassroots nontaxable amount					
49 Grassroots ceiling amount (150% of line 48(e))					
50 Grassroots lobbying expenditures					

Part VI-B **Lobbying Activity by Nonelecting Public Charities**
(For reporting only by organizations that did not complete Part VI-A) (See page 11 of the instructions.)

During the year, did the organization attempt to influence national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:	Yes	No	Amount
a Volunteers		✔	
b Paid staff or management (Include compensation in expenses reported on lines **c** through **h.**)		✔	
c Media advertisements		✔	
d Mailings to members, legislators, or the public		✔	
e Publications, or published or broadcast statements		✔	
f Grants to other organizations for lobbying purposes		✔	
g Direct contact with legislators, their staffs, government officials, or a legislative body		✔	
h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any other means		✔	
i Total lobbying expenditures (Add lines **c** through **h.**)			

If "Yes" to any of the above, also attach a statement giving a detailed description of the lobbying activities.

Part VII **Information Regarding Transfers To and Transactions and Relationships With Noncharitable Exempt Organizations** (See page 11 of the instructions.)

51 Did the reporting organization directly or indirectly engage in any of the following with any other organization described in section 501(c) of the Code (other than section 501(c)(3) organizations) or in section 527, relating to political organizations?

		Yes	No
a	Transfers from the reporting organization to a noncharitable exempt organization of:		
	(i) Cash	51a(i)		✔
	(ii) Other assets	a(ii)		✔
b	Other transactions:		
	(i) Sales or exchanges of assets with a noncharitable exempt organization	b(i)		✔
	(ii) Purchases of assets from a noncharitable exempt organization	b(ii)		✔
	(iii) Rental of facilities, equipment, or other assets	b(iii)		✔
	(iv) Reimbursement arrangements	b(iv)		✔
	(v) Loans or loan guarantees	b(v)		✔
	(vi) Performance of services or membership or fundraising solicitations	b(vi)		✔
c	Sharing of facilities, equipment, mailing lists, other assets, or paid employees	c		✔

d If the answer to any of the above is "Yes," complete the following schedule. Column (b) should always show the fair market value of the goods, other assets, or services given by the reporting organization. If the organization received less than fair market value in any transaction or sharing arrangement, show in column (d) the value of the goods, other assets, or services received:

(a) Line no	(b) Amount involved	(c) Name of noncharitable exempt organization	(d) Description of transfers, transactions, and sharing arrangements

52a Is the organization directly or indirectly affiliated with, or related to, one or more tax-exempt organizations described in section 501(c) of the Code (other than section 501(c)(3)) or in section 527? ▶ ☐ Yes ☑ No

b If "Yes," complete the following schedule:

(a) Name of organization	(b) Type of organization	(c) Description of relationship

Exhibit A
Form 990
Part 1 Line 8

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

The net capital gain realized was solely from the sales of publicly traded stocks and bonds through brokers. The total sales price was $123,082,059 with a cost basis of $113,937,731, resulting in a net gain of $9,114,328.

Exhibit B
Form 990
Part 1 Line 9

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
SPECIAL FUND RAISING EVENTS AND ACTIVITIES
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

Approximate No. of Events	Type of Event	Gross Revenue	Direct Benefit Expenses	Net Income
1	Telethon	$53,814,337	$15,359,679	$38,454,658
1,780	Sports Programs	21,064,976	3,798,041	17,266,935
300	Social Events	12,920,013	2,927,963	9,992,050
39,489	Special Events - Other	88,217,395	8,068,575	80,148,820
		$176,016,721	$30,154,258	$145,862,463 *

*Included in Direct Public Support Part I Line 1(a)

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
MDA RESEARCH GRANTS
FOR THE YEAR ENDED MARCH 31, 2005

FUNDING PROGRAM LEGEND

(EMG)	Earmarked Gift
(RF)	Research Fellowship
(RG)	Research Grant
(SG)	Special Grant
(NIDA)	New Investigator Development Award
(DG)	Research Development Grant
(TCL)	Tall Cedars of Lebanon
(TRAC)	Translational Research

ALABAMA

Birmingham - University of Alabama

David Curiel, M.D., Ph.D.

(RG) Exploiting transcytosis to facilitate adenovirus-mediated muscle cell transduction
$ 90,000

ARIZONA

Phoenix - St. Joseph's Hospital & Medical Center

Fu-Dong Shi, M.D., Ph.D.

(RG) Immune therapy with Atorvastatin in murine models for clinical application to myasthenia gravis
$ 80,000

Tucson - University of Arizona

Ronald E. Allen, Ph.D.

(RG) Regulation of skeletal muscle satellite cell activity
$ 100,000

Vince Guerriero, Ph.D.

(RG) Neuromuscular diseases and misfolded proteins
$ 56,195

David Labiner, M.D.

(SG) Neurology in the 21st Century: A Tribute to Dr. William A Sibley
$ 3,150

F. John Meaney, Ph.D.

(RG) Promoting health and well-being in boys with muscular dystrophy
$ 98,560

Lawrence Z. Stern, M.D.

(EMG) Research at the Uniiversity of Arizona Foundation
$ 163,068

CALIFORNIA

Davis - University of California

Ricardo Maselli, M.D.

(RG) Congenital myasthenic syndromes: Pathogenesis and treatment
$ 100,000

(RG) Microarray analysis of congenital myasthenic syndromes
$ 100,000

Emeryville - University of California

Hongkyun Kim, Ph.D.

(DG) A genetic study of muscular dystrophy in c. elegans
$ 45,000

Irvine - University of California

John H. Weiss, M.D., Ph.D.

(RG) Motor neuron ROS, glutamate transport disruption and amyotrophic lateral sclerosis (ALS)
$ 100,000

Sara Winokur, Ph.D.

(RG) Therapeutic approaches to aberrant myoblast differentiation in facioscapulohumeral dystrophy (FSHD)
$ 85,634

(RG) Investigation of FSHD as a nuclear envelope disease
$ 90,000

La Jolla - Salk Institute for Biological Studies

Kuo-Fen Lee, Ph.D.

(RG) The potential role of neuregulin in muscular dystrophy therapy
$ 80,000

La Jolla - Scripps Research Institute

Joel M. Gottesfeld, Ph.D.

(EMG) Restricted funds for FA research
$ 19,413

La Jolla - University of California

John Ross, JR. M.D.

(RG) Cardiac gene therapy in muscular dystrophies
$ 264,000

G. Diane Shelton, DVM, Ph.D.

(RG) Canine inflammatory myopathy: An animal model for human inflammatory myopathy
$ 66,712

Koji Yamanaka, M.D., Ph.D.

(DG) The role of ALS2 in the post-natal survival of human motor neurons
$ 45,000

Loma Linda - Musculoskeletal Disease Center

Ashok Kumar, Ph.D.

(RG) Myogenic signaling and Duchenne muscular dystrophy (DMD)
$ 75,000

Los Angeles - University of California

Giovanni Coppola, M.D.

(EMG) Restricted funds for support of Friedreich's ataxia research
$ 12,750

Michael Graves, M.D.

(EMG) For ALS research and care at UCLA
$ 7,500

Los Angeles - University of Southern California

Valerie Askanas, M.D., Ph.D.

(RG) Unfolded proteins in the pathogenesis of s-IBM
$ 100,000

(SG) Neurology Supplement - IBM Meeting
$ 20,000

Dr. Michel Baudry

(EMG) Restricted funds for support of Friedreich's ataxia
$ 29,930

W. King Engel, M.D.

(EMG) Restricted funds for neuromuscular disease research
$ 265,995

Sita Reddy, Ph.D.

(RG) Role of the muscleblind proteins in myotonic dystrophy (DM)
$ 110,000

(RG) Dissecting CNS dysfunction in myotonic dystrophy (DM)
$ 95,000

Zuo-Zhong Wang, Ph.D.

(RG) Role of agrin in muscle development and regeneration
$ 100,000

Pasadena - California Institute of Technology

David C. Chan, M.D., Ph.D.

(RG) Role of mitochondrial fusion in mitochondrial myopathies
$ 75,000

San Diego - San Diego State University

Sanford I. Bernstein, Ph.D.

(RG) Analysis and amelioration of defective protein folding in skeletal muscle
$ 96,084

San Francisco - California Pacific Medical Center

Robert G. Miller, M.D.

(EMG) Restricted funds for support of the MDA Clinic – Zimmerman Fund
$ 40,230

(EMG) Restricted funds for Forbes Norris MDA/ALS Center
$ 435,344

(RG) Minocycline in amyotrophic lateral sclerosis (ALS)
$ 74,457

(TRAC) MDA/ALS Web-based Database
$ 158,515

San Francisco - University of California

Marc Diamond, M.D.

(RG) Molecular and genetic modifiers of AR protein toxicity in spinal bulbar muscular atrophy (SBMA)
$ 100,000

(RG) Evaluation of Y-27632 in mouse models of SBMA
$ 100,000

Sachiko Hoshino, M.D., Ph.D.

(DG) CHC22 clathrin in normal and regenerating muscle
$ 45,000

Mei Li, M.D., Ph.D

(DG) Analysis of the effects of ROCK inhibitor Y-27632 in an SBMA mouse model
$ 45,000

Charles Ordahl, Ph.D.

(RG) Myogenic progenitor cells: A new muscle stem cell class
$ 80,068

Santa Cruz - University of California

Brian Ackley, Ph.D.

(DG) Nidogen and LAR phosphatase function during the formation of C. elegans neuromuscular junctions
$ 45,000

Stanford - Stanford University

Carmen Bertoni, Ph.D.

(DG) Oligonucleotide mediated gene repair for Duchenne muscular dystrophy (DMD)
$ 45,000

Guowei Fang, Ph.D.

(RG) Role of ubiquitin-mediated proteolysis in muscular dystrophies
$ 104,513

Thomas A. Rando, M.D., Ph.D.

(RG) Integrase-mediated gene therapy for muscular dystrophy
$ 120,000

Ching H. Wang, M.D., Ph.D.

(RG) A pilot therapeutic trial of hydroxyurea on type 1 spinal muscular atrophy (SMA)
$ 100,000

Hai Wu, Ph.D.

(DG) Calcineurin/NFAT signaling and the generation of V1 interneurons
$ 45,000

Yanmin Yang, M.D., Ph.D.

(RG) Functional characterization of gigaxonin
$ 103,668

COLORADO

Boulder - University of Colorado

Dawn Cornelison, Ph.D.

(DG) Signaling in satellite cells of mdx and other dystrophic muscle
$ 45,000

Hugo Olguin, Ph.D.

(DG) Pax-7 role in satellite cell self-renewal
$ 45,000

Bradley Olwin, Ph.D.

(RG) A molecular switch for satellite cells
$ 80,091

Denver - University of Colorado

William Betz, Ph.D.

(RG) Synaptic vesicle recycling in motor nerve terminals
$ 66,000

CONNECTICUT

New Haven - Yale University

Anton M. Bennett, Ph.D.

(RG) Muscle cell survival by protein tyrosine phosphatases in muscular dystrophy (MD)
$ 100,000

DISTRICT OF COLUMBIA

Washington - Children's National Medical Center

Marina Bakay, Ph.D.

(DG) Downstream consequences of biochemical defects in muscular dystrophies
$ 45,000

Diana Escolar, M.D.

(RG) High-dose prednisone in Duchenne muscular dystrophy (DMD)
$ 115,220

Eric Hoffman, Ph.D.

(EMG) Restricted funds for support of Duchenne muscular dystrophy research
$ 246,800

(RG) Transcriptional cascades in muscle regeneration
$ 90,000

FLORIDA

Gainesville - University of Florida

Lucia Notterpek, Ph.D.

(RG) Protein aggregation and degradation in Charcot-Marie-Tooth (CMT) disease
$ 114,634

Patana Teng-umnuay, M.D., Ph.D.

(DG) The role of phosphorylation in muscleblind function
$ 45,000

Jacksonville - Mayo Clinic Jacksonville

Terrone Rosenberry, Ph.D.

(RG) Interactions in the active site of acetylcholinesterase
$ 55,000

Miami - University of Miami

Antoni Barrientos, Ph.D.

(RG) Role of evolutionary conserved cytochrome c oxidase assembly factors
$ 75,000

Lisa L. Baumbach, Ph.D.

(RG) Final steps in discovery of the X-linked SMA gene
$ 101,742

Walter Bradley, M.D.

(EMG) Restricted funds for support of the Kessenich Family MDA/ALS Center
$ 155,739

Francisca Diaz, Ph.D.

(DG) A mouse model of cytochrome oxidase deficiency
$ 45,000

Alison Grossman, Ph.D.

(DG) Impact of psychosocial factors on ALS onset and disease progression
$ 45,000

Karl Magleby, Ph.D.

(RG) Modulation of BK channels by beta subunits
$ 71,053

Carlos Moraes, Ph.D.

(RG) Mitochondrial dysfunction in amyotrophic lateral sclerosis (ALS)
$ 97,824

Richard Rotundo, Ph.D.

(RG) Assembly of acetylcholinesterase and the synaptic basal lamina
$ 55,939

St. Augustine - University of Florida

Fumihito Ono, M.D., Ph.D.

(RG) Molecular basis of myasthenia-like syndromes in mutant synapses
$ 99,000

GEORGIA

Atlanta - Emory University

Tamara Caspary, Ph.D.

(DG) hennin: a novel mechanism of motor neuron specification
$ 45,000

Peter Hedera, M.D.

(RG) Molecular characterization of distal myopathy linked to chromosome 14q (MPD1)
$ 53,117

Jeffrey Myers, Ph.D.

(DG) Folding of myelin proteins implicated in peripheral neuropathy
$ 45,000

Grace Pavlath, Ph.D.

(RG) Regulation of myoblast migration and fusion by class III semaphorins
$ 80,000

Augusta - Medical College of Georgia

Lin Mei, M.D., Ph.D.

(RG) Erbin regulation of AChR expression
$ 90,000

Mark Becher, M.D.

(RG) Pathology of oculopharyngeal muscular dystrophy
$ 65,149

ILLINOIS

Chicago - Children's Memorial Institute for Ed. & Research

Christine DiDonato, Ph.D.

(RG) Gene therapy for animal models of spinal muscular atrophy (SMA)
$ 92,360

Chicago - Northwestern University

Robert Goldman, Ph.D.

(RG) Functional aspects of nuclear lamins in muscular dystrophy
$ 113,744

Teepu Siddique, M.D.

(RG) High throughput screening
$ 54,865

(SG) Primary lateral sclerosis diagnostic criteria conference
$ 5,000

Jianhua Yan, M.D.

(DG) A molecular target for amyotrophic lateral sclerosis (ALS) therapy: A gene for ALS/FTD
$ 45,000

Chicago - University of Chicago

James R. Brorson, M.D.

(RG) Glutamate receptors on corticospinal motor neurons and amyotrophic lateral sclerosis (ALS)
$ 38,125

Elizabeth McNally, M.D., Ph.D.
(RG) Stem cell transplantation in limb-girdle muscular dystrophy
$ 86,372

Raymond Roos, M.D.
(EMG) In memory of Barbara Anderson for ALS research
$ 5,965

Kamal Sharma, Ph.D.
(RG) SMN regulates motor neuron subtype identity
$ 100,000

Chicago - University of Illinois

David Featherstone, Ph.D.
(RG) Molecular mechanisms regulating extracellular glutamate
$ 74,179

Maria Krasilnikova
(EMG) Restricted funds for Friedreich's ataxia
$ 18,300

Maywood - Loyola University

Julio A. Copello, Ph.D.
(RG) Coordinated gating of ryanodine receptor channels
$ 80,000

Urbana - University of Illinois

Suzanne Berry, Ph.D.
(DG) Integrin enhancement of mesoangioblast cell therapy
$ 45,000

Stephen Kaufman, Ph.D.
(RG) Integrin alleviation of muscular dystrophy
$ 90,000

Derek Milner, Ph.D.
(DG) Alpha-7 beta-1 integrin mediated alleviation of muscular dystrophy
$ 45,000

INDIANA

Indianapolis - Indiana University

William J. Groh, M.D.
(RG) Predictors of sudden cardiac death in myotonic dystrophy
$ 46,285

Muncie - Ball State University

Derron Bishop, Ph.D.
(RG) Axon loss in a mouse model of amytrophic lateral sclerosis (ALS)
$ 82,289

IOWA

Iowa City - University of Iowa

Kevin P. Campbell, Ph.D.
(EMG) Restricted funds for limb-girdle research
$ 102,339

(RG) Development of treatment strategies for LGMD2I
$ 100,000

Shawn W. Flanagan, Ph.D.
(RG) The effect of mitochondrial anti-oxidant manipulation on mutant SOD1 cytotoxicity
$ 79,884

Lori Wallrath, Ph.D.
(RG) Drosophila as a model for Emery-Dreifuss muscular dystrophy
$ 79,398

Robert Weiss, M.D.
(RG) Stress-induced cardiac dysfunction in dystrophinopathy
$ 80,000

MAINE

Bar Harbor - Jackson Laboratory

Roger Sher, Ph.D.
(DG) Role of choline kinase beta in a murine muscular dystrophy
$ 45,000

Leonard Shultz, Ph.D.
(RG) SCID mouse models for stem cell therapy of muscular dystrophy
$ 60,000

MARYLAND

Baltimore - Johns Hopkins University

Daniel B. Drachman, M.D.
(EMG) Restricted funds for specific immunotherapy
$ 2,875

(RG) Specific immunotherapy of myasthenia gravis by gene transfer
$ 130,032

Douglas A. Kerr, M.D., Ph.D.
(RG) Utilization of embryonic stem cells in motor neuron diseases
$ 73,356

Vassilis Koliatsos, M.D.
(RG) Neural stem cells as experimental therapies for motor neuron disease
$ 167,071

Se-Jin Lee, M.D., Ph.D.
(RG) Regulation of myostatin latency
$ 139,102

Jeffrey D. Rothstein, M.D., Ph.D.
(RG) Excitatory amino acid transporters: Development of a therapy
$ 45,000

(EMG) Restricted funds for ALS research
$ 169,827

Shanthini Sockanathan, Ph.D.
(RG) The specification of spinal motor neurons
$ 80,000

Kathryn Wagner, M.D., Ph.D.
(DG) Effect of myostatin on satellite cells and muscle regeneration
$ 45,000

Baltimore - University of Maryland

Robert J. Bloch, Ph.D.
(RG) Intermediate filaments that organize the sarcolemma
$ 94,659

(RG) Signaling by the RhoGEF domain of obscurin
$ 83,642

Aikaterini Kontrogianni-Konstantopoulos, Ph.D.
(DG) Proteins organizing the sarcomere and the SR of skeletal muscle
$ 45,000

Bethesda - American College of Medical Genetics

Michael S. Watson, Ph.D.
(SG) ACMG 2005 Annual Clinical Genetics Meeting
$ 10,000

MASSACHUSETTS

Allston - Brigham and Women's Hospital

Ronan Walsh, MC, BCh, FRCPC
(TRAC) Clinical Research Training
$ 90,000

Boston - Boston University

William Lehman, Ph.D.
(RG) An atomic structure of dystrophin bound on F-actin
$ 74,291

Boston - Brigham and Women's Hospital

Steven Greenberg, M.D.

(RG) Single cell molecular methods in the inflammatory myopathies
$ 67,123

(RG) Blood gene expression profiles in autoimmune and inherited neuromuscular diseases
$ 26,283

Yaming Wang, M.D.

(RG) Study of Msx1-dedifferentiated cells for cell therapy of muscular dystrophies
$ 98,204

Karen Westerman, Ph.D.

(RG) Treatment of LGMD by homing therapeutic cells to muscle
$ 85,000

Boston - Children's Hospital

Alan H. Beggs, Ph.D.

(RG) Molecular genetics of congenital myopathies
$ 99,852

Emanuela Gussoni, Ph.D.

(RG) Myogenic potential and systemic delivery of human muscle SP cells
$ 45,000

Jeffrey Guyon, Ph.D.

(DG) Isolation of zebrafish with mutations causing muscular dystrophy
$ 45,000

Peter Kang, M.D.

(DG) Molecular basis of selective weakness in muscular dystrophy
$ 45,000

Giles Watts, Ph.D.

(DG) Molecular basis of h-IBM, Paget disease of bone and dementia
$ 45,000

Boston - Dana-Farber Cancer Institute

Christoph Handschin, Ph.D.

(DG) The role of PGC-1 in neuromuscular junction formation
$ 45,000

Boston - Harvard Medical School

Alfred L. Goldberg, Ph.D.

(RG) Protein breakdown in muscle in normal and disease states
$ 95,676

Boston - Harvard University

Andrew B. Lassar, Ph.D.

(RG) Cell cycle control of skeletal muscle differentiation
$ 80,000

Tiffany Reiter, Ph.D.

(DG) Heme oxygenase in motor neuron resistance to NO toxicity
$ 45,000

Cambridge - Whitehead Institute for Biomedical Research

Prakash Rao, Ph.D.

(DG) The role of microRNAs in myogenesis
$ 45,000

Charlestown - Massachusetts General Hospital

Susanna Benn, Ph.D.

(DG) Studies of the therapeutic effect of Hsp27 in amyotrophic lateral sclerosis (ALS) mice
$ 45,000

Robert Brown, Jr., D.Phil, M.D.

(RG) High throughput drug screening in SOD1-mediated amyotrophic lateral sclerosis
$ 88,110

Merit Cudkowicz, M.D., M.Sc.

(RG) Clinical trial of coenzyme Q10 in patients with amyotrophic lateral sclerosis (ALS)
$ 93,577

(RG) Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS
$ 113,769

Jonathan Francis, Ph.D.

(RG) Tetanus toxin fragment C for delivery of GDNF to the CNS
$ 71,972

Kimi Kong, Ph.D.

(DG) Investigation of stem cell therapy in Miyoshi myopathy and LGMD-2B
$ 45,000

Piera Pasinelli, Ph.D.

(DG) Proteomic analysis of apoptosis in GFP-labeled motor neurons of amyotrophic lateral sclerosis (ALS) mice
$ 45,000

Bryan J. Traynor, M.D.

(DG) The role of a start codon mutation of the SOD1 gene in amyotrophic lateral sclerosis (ALS) pathogenesis
$ 45,000

Clifford Woolf, M.D., Ph.D.

(RG) Hsp27 and motor neuron survival
$ 87,977

Waltham - Brandeis University

Carolyn Cohen, Ph.D.

(RG) Atomic structures of the muscle motor
$ 68,712

Watertown - Boston Biomedical Research Institute

Jeffrey B. Miller, Ph.D.

(RG) Dysferlinopathy model studies
$ 35,000

Worcester - University of Massachusetts

Davide Gabellini, Ph.D.

(DG) Definition of the molecular basis of facioscapulohumeral muscular dystrophy (FSHD)
$ 45,000

Laxman D. Gangwani, Ph.D.

(RG) To define the function of the Zinc Finger Protein ZPR1 in spinal muscular atrophy (SMA)
$ 110,575

Lawrence Hayward, M.D., Ph.D.

(RG) Autophagic stress and neuroprotection in SOD1-mediated amyotrophic lateral sclerosis (ALS)
$ 70,141

Jeanne Lawrence, Ph.D.

(RG) The role of nuclear structure in myotonic dystrophy (DM) and facioscapulohumeral dystrophy (FSHD)
$ 72,177

Rossella Tupler, M.D., Ph.D.

(EMG) Restricted funds for support of FSHD research
$ 1,177

MICHIGAN

Ann Arbor - University of Michigan

Denise A. Figlewicz, Ph.D.

(RG) New models of familial amyotrophic lateral sclerosis (FALS): Unmasking modifier genes
$ 84,713

Andrew Lieberman, M.D., Ph.D.

(RG) Altered androgen receptor function in Kennedy's disease
$ 74,297

(RG) A knock-in mouse model of Kennedy's disease
$ 100,000

Mark Russell, M.D.

(RG) Obscurin's role in myofibril assembly and structural support
$ 87,600

Detroit - Wayne State University

Gyula Acsadi, M.D., Ph.D.

(RG) Gene therapy for amyotrophic lateral sclerosis (ALS) by AAV mediated gene transfer
$ 93,696

John Kamholz, M.D., Ph.D.

(RG) Structural analysis of the extracellular domain of MPZ from patients with Charcot-Marie-Tooth type 1B (CMT1B)
$ 100,000

Jun Li, M.D., Ph.D.

(DG) The pathophysiology of conduction block in HNPP
$ 45,000

Michael E. Shy, M.D.

(RG) GDNF gene therapy in Charcot-Marie-Tooth type 1 (CMT1)
$ 100,000

(TRAC) CMT North American Database
$ 85,000

MINNESOTA

Minneapolis - Fairview University Medical Center

John Day, M.D., Ph.D.

(EMG) Restricted funds for research
$ 5,000

Minneapolis - University of Minnesota

Atsushi Asakura, Ph.D.

(RG) Transplantation of myogenic-endothelial progenitors for muscular dystrophies
$ 166,338

Christopher M. Gomez, M.D.Ph.D.

(RG) Cysteine proteases in the slow-channel myasthenic syndrome
$ 104,052

David Thomas, Ph.D.

(RG) Spectroscopic probes of muscle degeneration
$ 90,000

Wei Wang, M.D.

(DG) AChR epitopes restricted by DR and DQ molecules relevant to myasthenia gravis (MG)
$ 45,000

Rochester - Mayo Clinic

Andrew Engel, M.D.

(RG) Congenital myasthenic syndromes
$ 113,353

(EMG) Research at the Mayo Clinic
$ 10,000

Grazia Isaya, M.D., Ph.D.

(RG) Function and regulation of human frataxin
$ 86,400

(EMG) Restricted funds for FA research
$ 24,755

Ann M. Reed, M.D.

(RG) HLA genetics and chimerism in juvenile dermatomyositis
$ 78,933

Xiaolei Xu, Ph.D.

(RG) Genetic studies of titin in myofibrillogenesis and muscular dystrophy
$ 109,322

MISSISSIPPI

Jackson - University of Mississippi

Michael Hebert, Ph.D.

(RG) Regulation of coilin and SMN interaction by coilin associated proteins
$ 80,000

(EMG) Research for Friedrich's Ataxia
$ 17,800

MISSOURI

Columbia - University of Missouri

Dongsheng Duan, Ph.D.

(RG) AAV-mediated micro-dystrophin gene therapy of the mdx heart disease
$ 140,000

Christian Lorson, Ph.D.

(RG) Analysis of SMN exon 7 function
$ 117,312

Sinead O'Connell, M.D.

(RG) Motor axon pathway selection to muscle targets
$ 7,500

Kansas City - Stowers Institute for Medical Research

Olivier Pourquie, Ph.D.

(RG) Role of atrophins in patterning/differentiating early muscle precursers
$ 111,378

St. Louis - Washington University

Anne Connolly, M.D.

(RG) Role of complement 3 and B-cells in muscular dystrophy
$ 89,605

Paul Golumbek, M.D., Ph.D.

(DG) Non-immune effects of steroid treatment on Mdx/SCID mice
$ 45,000

Didier Hodzic, Ph.D.

(DG) Sun2-lamin B1: The end of [another] affair for muscular dystrophy?
$ 45,000

MONTANA

Great Falls - McLaughlin Research Institute

John Bermingham, Ph.D.

(RG) Positional cloning of the mouse hypomyelination mutation claw paw
$ 65,107

NEW JERSEY

Newark - University of Medicine and Dentistry of NewJersey

Langdon Miller, M.D.

(TRAC) PTC124 treatment for Duchenne muscular dystrophy
$ 1,023,460

Martha C. Nowycky, Ph.D.

(RG) TRPC channels and calcium in Duchenne muscular dystrophy
$ 100,887

Natalia Shirokova, Ph.D.

(RG) Metabolic control of calcium signaling in skeletal muscle
$ 84,784

NEW MEXICO

Albuquerque - University of New Mexico

Richard Cripps, D.Phil.

(RG) Transcriptional control of muscle remodeling in Drosophila
$ 78,377

NEW YORK

Albany - Albany Research Institute, Inc.

Arnulf H. Koeppen, M.D.

(EMG) Restricted funds for support of Friedreich's ataxia research
$ 22,000

Albany - State University of New York

Gang Li, Ph.D.

(DG) Inhibition of GluR2 AMPA receptors: A microsecond time resolution study
$ 45,000

Li Niu, Ph.D.

(RG) Discovery of aptamers to prevent excitotoxicity in amyotrophic lateral sclerosis (ALS)
$ 77,064

Bronx - Albert Einstein College of Medicine

Gary J. Bassell, Ph.D.

(RG) Axonal function of the survival of motor neuron protein
$ 75,000

Hanh Nguyen, Ph.D.

(RG) Analysis of skeletrophin, a novel essential component of muscle differentiation
$ 77,440

Buffalo - State University of New York

Luc Gosselin, Ph.D.

(RG) Mechanisms of failed regeneration in dystrophic muscle
$ 107,195

(SG) 5th Annual Dr. S. Mouchly Small Muscle Symposium
$ 2,000

Georgirene D. Vladutiu, Ph.D.

(RG) Improved diagnosis of metabolic diseases among the statin myopathies
$ 87,723

Ithaca - Cornell University

Jun Liu, Ph.D.

(TCL) Functional studies of nuclear membrane proteins emerin and MAN1 in C. elegans
$ 100,000

New York - Columbia University

Salvatore DiMauro, M.D.

(RG) Pathogenesis of the human glycogenoses
$ 95,000

(RG) Studies of human mitochondrial myopathies
$ 100,000

Robert Gilkerson, Ph.D.

(TCL) Mitochondrial DNA nucleoids: Organization and dynamic
$ 45,000

Veronica Hinton, Ph.D.

(RG) Cognitive phenotype associated with Duchenne muscular dystrophy (DMD)
$ 42,949

Michio Hirano, M.D.

(RG) Molecular pathogenesis and treatment of MNGIE
$ 60,407

(RG) Pathogenesis of mitochondrial myopathy due to thymidine kinase 2 deficiency
$ 100,942

Edward Laufer, Ph.D.

(RG) Control of limb motor axon dorsal-ventral projection
$ 68,222

Chung-Ming Lin, Ph.D.

(DG) Studies of muscular dystrophy in dystonia musculorum mice
$ 45,000

Hiroshi Mitsumoto, M.D.

(RG) Genetic-environmental epidemiology in amyotrophic lateral sclerosis (ALS)
$ 137,628

(SG) ALS Research Group Annual Meeting
$ 4,496

Makiko Nagai, M.D., Ph.D.

(RF) Stem cell research for ALS
$ 45,000

Cecilia Ostlund, Ph.D.

(DG) The role of A-type laminins in Emery-Dreifuss muscular dystrophy (EDMD)
$ 45,000

Howard J. Worman, M.D.

(RG) Abnormal Smad2/3-mediated signal transduction in nuclear envelopathies
$ 109,646

New York - Cornell University

M. Flint Beal, M.D.

(RG) Testing novel therapeutics in a transgenic mouse model of amyotrophic lateral sclerosis (ALS)
$ 73,058

Giovanni Manfredi, M.D., Ph.D.

(RG) Bcl-2 and adenine nucleotide translocator in mitochondrial disorders
$ 81,364

New York - Mount Sinai School of Medicine

Dale Lange, M.D.

(EMG) Restricted for ALS research
$ 50,000

Giulio Pasinetti, M.D., Ph.D.

(RG) The role of cyclooxygenase-2 inhibitors in a model of ALS neurodegeneration
$ 87,698

David A. Sassoon, Ph.D.

(RG) Functional analysis of a potential regulator of muscle stem cells
$ 90,000

Rochester - University of Rochester

Emma Ciafaloni, M.D.

(RG) The pathophysiology of hypersomnolence in myotonic dystrophy
$ 48,886

Robert Griggs, MD

(SG) Pathogenesis and treatment of the periodic paralyses
$ 11,860

(SG) Deflazacort vs. Prednisone Date Publication
$ 25,464

(SG) Optimizing Medical Treatment for Duchenne Muscular Dystrophy
$ 10,000

Richard T. Moxley, M.D.

(TRAC) MD Cooperative Center Supplement - Rochester
$ 499,999

Charles A. Thornton, M.D.

(RG) Molecular pathogenesis of oculopharyngeal muscular dystrophy (OPMD)
$ 100,000

NORTH CAROLINA

Chapel Hill - Asklepios Biopharmaceutical Inc.

R. Jude Samulski, Ph.D.

(TRAC) Phase I/II Study of Mini-Dystrophin Gene in AAV Vector
$ 640,261

Chapel Hill - University of North Carolina

Nikolay V. Dokholyan, Ph.D.

(RG) Uncovering the origins of mutant SOD1 toxicity in familial ALS
$ 107,735

Da-Zhi Wang, Ph.D.

(RG) Control of skeletal muscle differentiation and function by SRF and myocardin family of transcription factors
$ 80,000

Charlotte - Carolinas Medical Center

Qi Long Lu, Ph.D.

(RG) Systemic delivery of antisense oligonucleotides for the treatment of DMD
$ 120,000

Durham - Duke University

John R. Gilbert, Ph.D.

(RG) Genetic and expression studies of non-chromosome 4 facioscapulohumeral muscular dystrophy (non-4q FSHD)
$ 103,416

Dwight Koeberl, M.D., Ph.D.

(RG) Preclinical studies with AAV vectors in acid maltase deficiency (AMD)
$ 92,118

OHIO

Cincinnati - University of Cincinnati

John Quinlan, M.D.

(RG) Prevention and treatment of cardiomyopathy in mdx mice
$ 100,000

Cleveland - Case Western Reserve University

M. Edward Medof, M.D., Ph.D.

(RG) An active model of myasthenia gravis (MG) with targeted treatment
$ 108,313

Cleveland - University of Kentucky Research Foundation

Stephen Testa, Ph.D.

(RG) The development and assessment of a therapeutic strategy for myotonic dystrophy (DM)
$ 62,192

Columbus - Children's Research Institute

Paul Martin, Ph.D.

(RG) UDP-Ga1NAc as a therapeutic in mdx mice
$ 72,721

Jerry Mendell, M.D.

(TRAC) Transfer of alpha-sarcoglycan gene to LGMD2D patients
$ 60,000

(RG) S. Mouchly Small Scientific Award
$ 10,000

Columbus - Ohio State University

Jerry R. Mendell, M.D.

(EMG) Restricted funds for gene therapy research
$ 47,843

Thomas Prior, Ph.D.

(PPG) WAVE-based mutation analysis for MD
$ 77,600

OREGON

Eugene - University of Oregon

J. Andrew Berglund, Ph.D.

(RG) Understanding the RNA structure responsible for myotonic dystrophy
$ 97,951

Janis Weeks, Ph.D.

(RG) A novel screen for muscle and motoneuron death and protection genes
$ 62,800

PENNSYLVANIA

Danville - Geisinger Clinic

Yiumo Chan, Ph.D.

(TCL) The assembly of the sarcolygcans and their role in muscular dystrophies
$ 94,571

Hershey - Pennsylvania State University

James R. Connor, Ph.D.

(RG) Genotyping analysis for Hfe mutations in amyotrophic lateral sclerosis
$ 80,032

Philadelphia - Children's Hospital of Philadelphia

Carsten Bonnemann, M.D.

(TCL) Molecular mechanisms of dominant negative congenital muscular dystrophy type Ullrich (UCMD)
$ 75,000

David R. Lynch, M.D., Ph.D.

(PPG) Clinical measures in Friedreich's ataxia (FA)
$ 160,658

David Pleasure, M.D.

(RG) Neuropilin-2 facilitates axonal regeneration in PNS
$ 95,064

Weidong Xiao, Ph.D.

(RG) Optimization of AAV vector for gene therapy of neuromuscular diseases
$ 102,090

Philadelphia – Drexel University

Terry Heiman-Patterson, M.D.

(EMG) Restricted funds for support of the MDA/ALS Center of Hope
$ 170,288

Philadelphia - Thomas Jefferson University

Michael P. King, Ph.D.

(RG) Correction of mtDNA mutations resulting in myopathies
$ 89,329

Diane E. Merry, Ph.D.

(RG) Pathogenesis and treatment of a mouse model of spinal and bulbar muscular atrophy (SBMA)
$ 75,000

Philadelphia - University of Pennsylvania

Sasha Bogdanovich, M.D.

(DG) Myostatin blockade for improvement of limb-girdle muscular dystrophy phenotype
$ 45,000

Thomas Kadesch, Ph.D.

(RG) The control of myoblast proliferation and differentiation by Notch
$ 154,636

Stephen Kolb, M.D., Ph.D.

(DG) Quantitative measurement of SMN complex proteins in SMA patients
$ 45,000

Hong Lin, Ph.D.

(DG) Role of NF-L RNA-binding protein in protein aggregation and neurodegeneration in amyotrophic lateral sclerosis (ALS)
$ 44,550

Christiane Massicotte, DVM, MS, Ph.D.

(RG) Alterations in mutant protein Cx32 trafficking which cause Charcot-Marie-Tooth (CMT) disease
$ 79,702

Joseph W. Sanger, Ph.D.

(RG) Titin and myosin in myofibril assembly: Insights into muscle diseases
$ 96,184

H. Lee Sweeney, Ph.D.

(TRAC) Preclinical studies to support clinical trials for muscular dystrophy
$ 224,796

J. Paul Taylor, M.D., Ph.D.

(RG) Characterizing a Drosophila model of spinal bulbar muscular atrophy (SBMA)
$ 96,925

Pittsburgh - Children's Hospital of Pittsburgh

Johnny Huard, Ph.D.

(RG) Improving skeletal and cardiac muscle function via stem cell transplantation
$ 100,000

Pittsburgh - University of Pittsburgh

Paula R. Clemens, M.D.

(RG) Adenoviral vector targeting for muscle gene transfer
$ 85,000

Joseph C. Glorioso, Ph.D.

(TRAC) MD Cooperative Center Supplement - Pittsburgh
$ 500,000

Chunping Qiao, M.D., Ph.D.

(DG) Congenital muscular dystrophy (CMD) gene therapy with novel AAV-mini-agrin vectors
$ 45,000

Xiao Xiao, Ph.D.

(RG) AAV vectors for stem cell-mediated Duchenne muscular dystrophy gene therapy
$ 100,000

TENNESSEE

Memphis - University of Tennessee

Harry Jarrett, Ph.D.

(RG) Muscular dystrophy and cell signaling
$ 90,000

TEXAS

Austin - University of Texas

Ruth A. Hagerman, Ph.D.

(RG) Effect of mutations in complex III on ubiquinone stability
$ 66,355

College Station - Texas A&M University

Emily Wilson, Ph.D.

(RG) Arterial remodeling in mouse models of muscular dystrophy
$ 93,005

Dallas - FASEB

Daniel Garry, MD, PhD

(SG) Skeletal muscle satellite and stem cell population
$ 10,000

Dallas - Texas Scottish Rite Hospital

Susan T. Iannaccone, M.D.

(EMG) Restricted funds for SMA research
$ 40,000

Dallas - UT Southwestern Medical Center

George N. DeMartino, Ph.D.

(RG) Regulation of muscle protein degradation by the proteasome
$ 88,810

Jeffrey Elliott, M.D.

(EMG) Restricted funds for ALS research
$ 73,032

Ronald G. Haller, M.D.

(RG) Exercise therapy for mitochondrial myopathies
$ 125,997

Osamu Nakagawa, M.D., Ph.D.

(RG) Roles of MEF2-regulated kinase Stk23 in muscular dystrophy
$ 65,000

Eric N. Olson, Ph.D.

(RG) Control of muscle growth by a novel small molecular
$ 60,000

Galveston - University of Texas

Tetsuo Ashizawa, M.D.

(RG) Accelerated cellular senescence in myotonic dystrophy type 1
$ 79,590

Premkumar Christadoss, M.D.

(RG) New model of ocular myasthenia gravis in HLA transgenic mice
$ 119,323

Henry F. Epstein, M.D.

(RG) Regulation of myotonic dystrophy protein kinase (DMPK) in brain
$ 82,371

Erdem Tuzun, M.D.

(DG) Effector roles of C1q, IL-6 and TNF-alpha in murine myasthenia gravis (MG)
$ 45,000

Houston - Baylor College of Medicine

Stanley H Appel, M.D.

(EMG) Restricted funds for ALS research
$ 7,568

(RG) Immune mechanisms in amyotrophic lateral sclerosis (ALS)
$ 110,000

Michael A. Barry, Ph.D.

(RG) Development of metabolically biotinylated gene therapy vectors
$ 141,658

Aladin M. Boriek, Ph.D.

(RG) Signal transduction in genetically altered dystrophic mice
$ 75,000

Thomas A. Cooper, M.D.

(RG) Splicing mis-regulation in the central nervous system in myotonic dystrophy
$ 104,987

Gabriella D'Arcangelo, Ph.D.

(RG) Reelin signaling in Schwann cell development and function
$ 100,000

William J. Durham, Ph.D.

(DG) Oxidative metabolism and contractile function in dystrophic skeletal muscle
$ 45,000

Margaret Goodell, Ph.D.

(RG) Stem cell transplantation for therapy of neuromuscular disease
$ 95,000

Yasuo Hamamori, M.D., Ph.D.

(RG) Regulation of muscle differentiation by notch effectors
$ 95,294

Susan L. Hamilton, Ph.D.

(RG) Mouse models of central core disease
$ 92,248

Kathyjo Jackson, Ph.D.

(DG) Improvement of bone marrow incorporation into skeletal muscle
$ 45,000

Andrea Ladd, Ph.D.

(DG) Developmental alternative splicing programs in normal and DM muscle
$ 45,000

Irina Serysheva, Ph.D.

(RG) Structure-function correlation's within skeletal muscle L-type Ca2+ channel
$ 78,366

G. Jackson Snipes, M.D., Ph.D.

(RG) Protein degradation in Charcot-Marie-Tooth disease
$ 100,000

Houston - Methodist Hospital

Jenny Henkel, Ph.D.

(DG) The role of dendritic cells in ALS pathogenesis
$ 45,000

Stanley Appel, M.D.

(EMG) Restricted funds for ALS Research
$ 15,405

Houston - University of Houston

Werner Hoch, Ph.D.

(RG) Generation of an animal model for a new form of myasthenia gravis (MG)
$ 75,000

Houston - University of Texas

Vasanthi Jayaraman, Ph.D.

(RG) High throughput screening for AMPA receptor antagonists for ALS
$ 100,000

William Klein, Ph.D.

(RG) Using myogenin to manipulate muscle stem cells
$ 74,353

Robert A. Schulz, Ph.D.

(RG) Calcineurin function in muscle development
$ 90,000

San Antonio - University of Texas

Eileen Lafer, Ph.D.

(RG) Basic mechanisms underlying neurotransmission
$ 92,422

Holly Van Remmen, Ph.D.

(RG) Alterations in mitochondrial function in the initiation and progression of ALS
$ 100,000

UTAH

Logan - Utah State University

Brett A. Adams, Ph.D.

(RG) Novel signaling proteins in motoneurons
$ 70,000

Katarina Stroffekova, Ph.D.

(RG) CaM as a calcium sensor of skeletal muscle DHPR and its implication in EC coupling
$ 85,000

Salt Lake City - University of Utah

Mark Bromberg, M.D., Ph.D.

(EMG) Restricted for the support of the MDA clinic at the University of Utah School of Medicine
$ 27,871

Kathleen Clark, Ph.D.

(DG) A potential role for muscle LIM protein in limb girdle muscular dystrophy (LGMD)
$ 45,000

Michael T. Howard, Ph.D.

(DG) Restorative decoding of premature stop codon and frameshift mutations
$ 45,000

Kathryn J. Swoboda, M.D.

(RG) Refinement of outcome parameters for clinical trials in SMA
$ 44,963

(EMG) SMA Research at the University of Utah School of Medicine
$ 50,000

VIRGINIA

Charlottesville - University of Virginia

Mani Mahadevan, M.D.

(TCL) Inducible transgenic mouse model of myotonic dystrophy type 1 (DM1)
$ 169,026

Norfolk - Eastern Virginia Medical School

Earl Godfrey, Ph.D.

(RG) Role of nitric oxide synthase pathway in neuromuscular development
$ 90,450

WASHINGTON

Seattle - University of Washington

William Catterall, Ph.D.

(RG) Regulation of Ca2+ channel by protein phosphorylation
$ 88,238

Jeffrey S. Chamberlain, Ph.D.

(TRAC) MD Cooperative Center Supplement - Seattle
$ 499,968

Ying-Zhang Chen, M.D., Ph.D.

(DG) Genetic analysis in amyotrophic lateral sclerosis 4 (ALS4)
$ 45,000

Stanley C. Froehner, Ph.D.

(RG) Identifying the genetic basis of a novel form of congenital muscular dystrophy
$ 100,000

(SG) 2nd Seattle Muscular Dystrophy Conference
$ 7,690

Paul Gregorevic, Ph.D.

(DG) Techniques for therapeutic gene delivery to cardiac and skeletal muscles
$ 45,000

Stephen D. Hauschka, Ph.D.

(RG) Regulatory cassettes for expressing therapeutic proteins in diseased muscle
$ 112,500

Albert La Spada, M.D., Ph.D.

(RG) Modeling motor neuron degeneration in spinal bulbar muscular atrophy (SBMA)
$ 101,208

Sheng Li, M.D., Ph.D.

(DG) Developing bone marrow stem cell based ex vivo gene therapy for Duchenne muscular dystrophy (DMD)
$ 45,000

WISCONSIN

Madison - University of Wisconsin

James M. Ervasti, Ph.D.
(RG) Role of costameric actin in dystrophinopathies
$ 94,593

Jon A. Wolff, M.D.
(RG) Intravascular injection of naked plasmid DNA into the mdx mouse model for Duchenne muscular dystrophy (DMD)
$ 90,000

AUSTRALIA

Brisbane Old - University of Queensland

Louise Cahill
(EMG) Restricted funds for Friedreich's ataxia research
$ 21,660

Concord - University of Sydney

Garth Nicholson, Ph.D.
(RG) Construction and characterization of hereditary sensory neuropathy type I transgenic mouse
$ 47,065

Fitzroy - St Vincent's Hospital Melbourne

Robert Kapsa, Ph.D.
(RG) Improved delivery of wt dystrophin locus in the mdx mouse
$ 66,545

Melbourne - Murdoch Children's Research Institute

Panos Ioannou, Ph.D.
(EMG) Restricted for Friedreich's ataxia research
$ 20,000

(RG) Novel approaches to the therapy of Friedreich's ataxia
$ 100,000

Martin Delatycki, M.D.
(EMG) Restricted for Friedreich's ataxia research
$ 25,500

Melbourne - University of Melbourne

Gordon Lynch, Ph.D.
(RG) Growth factor therapy for improving muscle function in muscular dystrophy
$ 83,264

David Thorburn, Ph.D.
(RG) Finding the pathogenic mechanisms by which different genes cause mitochondrial complex I deficiency
$ 97,179

Murdoch - Murdoch University

John McC. Howell, DVSc, Ph.D.
(RG) Gene transfer to mature muscle in myophosphorylase deficiency
$ 82,080

Perth - University of Western Australia

Stephen D. Wilton, Ph.D.
(RG) Reducing the severity of DMD by redirecting pre-mRNA splicing
$ 108,864

Randwick - University of New South Wales

Des Richardson, B.Sc., M.Sc., Ph.D., D.Sc.
(RG) The role of iron in Friedreich's ataxia and the use of iron chelation therapy
$ 128,793

Sydney - Children's Hospital at Westmead

Sandra Cooper, Ph.D.
(DG) The role of dysferlin in the pathogenesis of limb girdle muscular dystrophy
$ 44,832

Sydney - Victor Chang Cardiac Research Inst.

Peter Currie, Ph.D.

(RG) Characterization of zebrafish dystrophin mutants
$ 70,000

Toowoomba - University of Southern Queensland

Andrew Hoey, Ph.D.

(RG) Cardiac dysfunction in Duchenne muscular dystrophy (DMD)
$ 69,152

AUSTRIA

Vienna - Medical University of Vienna

Dr. Barbara Scheiber-Mojdehkar

(EMG) Restricted funds for FA research
$ 20,255

BELGIUM

Leuven - VIB

Peter Carmeliet, Ph.D., M.D.

(RG) Therapeutic potential of VEGF for amyotrophic lateral sclerosis (ALS)
$ 124,482

Mons - University of Mons-Hainaut

Frederique Coppee, Ph.D.

(DG) Characterization of DUX4c and its role in facioscapulohumeral dystrophy (FSHD)
$ 44,712

CANADA

London - University of Western Ontario

Christen Shoesmith, BSc, M.D.

(TRAC) Clinical Research Training
$ 74,200

Michael Strong, M.D, FRCPC

(RG) The regulation of microglial activation in amyotrophic lateral sclerosis (ALS)
$ 81,846

Montreal - McGill University

Jeffrey N. Agar, Ph.D.

(DG) Mechanisms and consequences of altered protein solubility in amyotrophic lateral sclerosis (ALS)
$ 44,820

Brendan J. Battersby, Ph.D.

(DG) New animal model for mitochondrial diseases
$ 44,990

Salvatore Carbonetto, Ph.D.

(RG) Dystroglycan associated proteins in synaptic vesicle recycling
$ 90,000

Heather Durham, Ph.D.

(RG) Mechanisms of motor neuron vulnerability to disease
$ 89,419

George Karpati, M.D.

(RG) Molecular therapies for dystrophin deficiency
$ 80,000

Basil Petrof, M.D.

(RG) Plasmid-mediated delivery of therapeutic genes in muscular dystrophy
$ 88,588

Eric Shoubridge, Ph.D.

(RG) Assembly of cytochrome c oxidase in mitochondrial myopathy
$ 82,393

Montreal - Montreal General Hospital

Guy Rouleau, M.D., Ph.D.

(RG) Investigation of the pathogenesis of oculopharyngeal muscular dystrophy (OPMD)
$ 100,000

(RG) Identification and characterization of the ALS3 gene
$ 100,000

Ottawa - Children's Hospital of Eastern Ontario

Robert G. Korneluk, Ph.D.

(RG) Therapeutic potential of apoptosis suppression for myotonic dystrophy (DM)
$ 99,440

Alex MacKenzie, M.D., Ph.D.

(RG) Compound testing in organotypic cultures of spinal muscular atrophy (SMA) mouse model spinal cords
$ 77,000

Ottawa - Ottawa Health Research Institute

Rashmi Kothary, Ph.D.

(RG) The role of sodium channel 8a in skeletal and cardiac muscle function
$ 100,000

Lynn A. Megeney, Ph.D.

(RG) Characterizing the role of the TC10/JNK1 atrophic pathway in dystrophic muscle
$ 100,000

Michael Rudnicki, Ph.D.

(RG) Molecular regulation of satellite cell function
$ 130,000

Ottawa - University of Ottawa

Stephen H. Gee, Ph.D.

(RG) The role of diacylglycerol kinase-zeta and syntrophins in myoblast fusion
$ 81,930

Bernard Jasmin, Ph.D.

(RG) Role of calcineurin signalling in the regulation of utrophin in skeletal muscle
$ 124,700

Luc Sabourin, Ph.D.

(RG) Role of SLK in myoblast migration
$ 98,709

Quebec - Laval University

Francois Berthod, Ph.D.

(RG) Development of a tissue-engineered model of spinal cord to study amyotrophic lateral sclerosis (ALS)
$ 71,569

Jack Puymirat, M.D., Ph.D.

(RG) Stratagems in vitro for a gene therapy for myotonic dystrophy
$ 33,594

Toronto - Hospital For Sick Children

Christopher Pearson, Ph.D.

(RG) DNA replication, DNA repair and drug-induced CTG repeat instability in DM1 patient cells
$ 75,000

Toronto - University of Toronto

Anthony Gramolini, Ph.D.

(DG) Generation and characterization of transgenic mouse models of central core disease (CCD)
$ 44,550

Vancouver – University of British Columbia

Fabio Rossi, M.D., Ph.D.

(RG) Identification and engineering of circulating myogenic progenitors
$ 90,000

CHILE

Santiago – Catholic University of Chile

Enrique Brandan, Ph.D.

(RG) DMD fibrosis: Role of CTGF, LRP and proteoglycans
$ 63,982

CYPRUS

Nicosia – Cyprus Institute of Neurology and Genetics

Kyproula Christodoulou, Ph.D.

(RG) Neuromuscular diseases in Eastern Mediterranean countries
$ 65,930

FRANCE

Gif sur Yvette - CNRS

Sabine De La Porte, Ph.D.

(RG) Finding the best NO-related compound for treating Duchenne and Becker dystrophies
$ 28,350

Illkirch cu de Strasbourg - INSERM

Helene Puccio, Ph.D.

(EMG) Restricted funds for Friedreich's ataxia research
$ 11,500

Montpellier - Centre National de la Recherche Scientifique

Anne Fernandez, Ph.D.

(RG) A comparative proteomic analysis of muscle degeneration in FSHD
$ 60,000

GERMANY

Aachen - RWTH Aachen

Christoph M. Fahlke, M.D.

(RG) Modification of CIC-1 function by cytoplasmic domains in normal and myotonic muscle
$ 95,349

Essen - University Hospital of Essen

Helge Amthor, M.D.

(DG) Evaluating the adverse effects of myostatin loss on normal and dystrophic skeletal muscle
$ 44,965

GREECE

Athens - Hellenic Pasteur Institute

Socrates Tzartos, Ph.D.

(RG) Autoantibody depletion and down-regulation in myasthenia gravis (MG)
$ 97,900

ISRAEL

Jerusalem - Hebrew University

Millet Treinin, Ph.D.

(RG) Identification and characterization of genes needed for nAChR mutation
$ 63,074

Rehovot – Weizmann Institute of Science

David Yaffe, Ph.D.

(RG) The DMD gene products in mammals and drosophila: Functional implications
$ 92,061

Tel-Aviv – Open University of Israel

Miriam Souroujon, Ph.D.

(RG) Immunotherapies for experimental myasthenia
$ 82,720

ITALY

Milan - Istituto Scientifico San Raffaele

Giulio Cossu, M.D.

(RG) Isolation, in vitro expansion and characterization of human mesoangioblasts for the cell
$ 89,000

Monterotondo Scalo - Dulbecco Telethon Institute

Livio Pellizzoni, Ph.D.

(RG) Characterization of SMN interactions in the mouse spinal cord
$ 49,600

Napoli – TIGEM

Elena I. Rugarli, M.D.

(RG) Towards a therapy for hereditary spastic paraplegia due to paraplegin deficiency
$ 65,560

Rome – Dulbecco Telethon Institute

Pier Lorenzo Puri, M.D., Ph.D.

(RG) Deacetylase inhibitors as a pharmacological tool for muscular dystrophies
$ 90,000

MEXICO

Mexico City - CINVESTAV-IPN

Bulmaro Cisneros, Ph.D.

(RG) Molecular mechanism of the inhibition of neuronal differentiation induced by the DM expanded CTG repeats
$ 32,950

NETHERLANDS

Leiden - Leiden University

Silvere van der Maarel, Ph.D.

(SG) International FSHD Workshop
$ 4,750

(EMG) Restricted funds for facioscapulohumeral muscular dystrophy research
$ 53,000

(RG) Epigenetic studies of facioscapulohumeral muscular dystrophy (FSHD)
$ 119,590

Silvere van der Maarel, Ph.D.

(RG) Comparative analysis of 4q-linked FSHD, non-4q-linked FSHD, and ICF syndrome
$ 88,961

Judith C. T. van Deutekom, Ph.D.

(RG) Antisense therapy in different Duchenne muscular dystrophy (DMD) mouse models
$ 100,000

Nijmegen - University of Nijmegen

Berend Wieringa, Ph.D.

(RG) Treatment of somatic (CTG)n repeat instability in myotonic dystrophy (DM)
$ 103,475

PORTUGAL

Lisboa – University of Lisboa

Mario do Carmo-Fonseca, M.D., Ph.D.
(RG) Profiling alternative splicing in muscular dystrophies
$ 100,000

SINGAPORE

Singapore – National Cancer Centre

Mac Mengfatt Ho, D.Phil
(RG) Functional proteomic analysis of dysferlinopathy and dysferlin-mediated membrane repair
$ 70,152

SPAIN

Barcelona – Center for Genomic Regulation

Pura Munoz Canoves, Ph.D.
(RG) Role of the plasminogen activation system in mdx dystrophinopathy
$ 100,000

Lleida -University of Lleida

Jordi Tamarit, M.D.
(EMG) Restricted for Friedreich's ataxia research
$ 12,500

SWEDEN

Huddinge - Karolinska Institute

Nils-Goran Larsson, M.D., Ph.D.
(RG) Mechanisms of pathology in a mouse model for mitochondrial myopathy
$ 79,970

SWITZERLAND

Basel - University of Basel

Markus A. Ruegg, Ph.D.
(RG) Treatment of congenital muscular dystrophy (CMD) by an agrin minigene
$ 92,716

UNITED KINGDOM

Dundee - University of Dundee

Miguel Maroto, Ph.D.
(DG) Role of notch signaling in patterning/differentiation of early muscle precursors
$ 45,000

London - Imperial College School of Medicine

Richard Festenstein, MB, MRCP, PhD
(RG) Epigenetic modifiers as disease modifying agents in myotonic dystrophy?
$ 80,000

London - King's College Hospital

Michael Rose, M.D.
(RG) US Validation of a neuromuscular disease quality of life measure
$ 53,946

London - University College London

Linda Greensmith, Ph.D.
(RG) Treatment of ALS with Arimoclomol, a novel inducer of heat shock proteins
$ 107,140

Nottingham - University of Nottingham

J. David Brook, Ph.D.
(RG) The role and interactions of muscleblind proteins in myotonic dystrophy
$ 150,000

Oswestry - RJAH Hospital

Glenn Morris, D.Phil.

(TRAC) A monoclonal antibody resource for genetic neuromuscular diseases
$ 117,437

Oxford - University of Oxford

Kay E. Davies, MA, D.Phil.

(RG) Analysis of the role of syncoilin in muscle disease
$ 86,047

(RG) Increased utrophin expression in therapy of DMD
$ 99,260

Total Grants and Awards	$ 32,171,171
Return of Unexpended Funds	(991,937)
Cancellations of Prior Year Awards	(611,389)
	$ 30,567,845
Total Grants and Awards Outstanding at 8/31/05	$ 18,551,565

Exhibit D
Form 990
Part II Line 42
Part IV Line 57

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
SCHEDULE OF FIXED ASSETS, DEPRECIATION AND AMORTIZATION
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

	3/31/2004 Balance	Removal of Fully Depreciated Assets	Acquisitions & Disposals	Depreciation, Amortization & Other Expenses	3/31/2005 Balance
Land and Improvements	$2,183,300				$2,183,300
Building	7,904,956				7,904,956
Furniture & Equipment	6,475,956	($1,151,219)	$1,493,944		6,818,681
Accumulated Depreciation- Building and Furniture & Equipment	(6,018,479)	1,151,219		($1,522,755)	(6,390,015)
	$10,545,733	$0	$1,493,944	($1,522,755)	$10,516,922

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
SCHEDULE OF INVESTMENTS - SECURITIES

STOCKS	3/31/2004	3/31/2005
Abbott Laboratories	$4,114,233	$0
Ace Ltd	0	4,127,000
American International Group Inc	2,140,500	3,326,706
American Vantage Companies	9,840	5,700
Applied Materials Inc	0	2,843,750
Autonation, Inc.	2,557,500	0
Barretville Bank & Trust 100,000th	UNPRICED	UNPRICED
Cisco Sys Inc	0	4,472,500
Citigroup Inc	2,585,000	4,497,550
Comcast	4,177,500	0
Walt Disney Co	0	4,309,500
EMC Corp-Mass	0	3,696,000
General Electric	3,819,334	4,507,500
Goldman Sachs	339,159	354,360
Goodrich Pete Corp New	2,047,595	4,226,000
Hewlett Packard Co	4,572,568	0
Intel Corp	2,720,000	4,065,250
Intl Business Machines Corp	3,680,029	4,121,238
Johnson & Johnson	2,028,800	0
JP Morgan Chase	0	4,325,000
Jetblue Airways Corp	0	3,332,000
Lucent Technologies	0	3,300,000
WTS Lucent Technologies	0	4,439
Max Re Capital Ltd	2,260,000	0
Merk & Co	3,096,614	0
Microsoft Corp	3,116,250	3,625,500
Nasdaq 100 Trust Ser 1	3,584,000	0
Natural Gas Company VA Inc Class A	UNPRICED	UNPRICED
Networks Associates Inc.	3,600,000	0
Old Repbulic International Corp	4,912,000	0
Oracle Corp	3,000,000	2,496,000
Pfizer Inc	2,641,087	3,950,272
SBC Communications Inc	0	3,553,500
Sirus Satellite Radio Inc	3,060,000	1,124,000
Southern Un Co	4,194,147	0
State Street Bank	57,708	0
Texas Instruments Inc	0	4,460,750
Time Warner Inc	3,793,500	0
Total Management Inc	UNPRICED	UNPRICED
Travelers Prop Casualty	3,430,000	0
UBS PaineWebber Inc Access Account	140,495	0

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
SCHEDULE OF INVESTMENTS - SECURITIES

STOCKS	3/31/2004	3/31/2005
US Bancorp Del New	3,456,250	0
Valley Cmnty Bancshares Inc	3,520	0
Wal-Mart Stores Inc	0	3,758,250
TOTAL STOCKS	79,137,629	78,482,765
CLOSED END FUNDS		
Nasdaq 100 Trust Ser 1	0	4,571,250
TOTAL	0	4,571,250
BONDS AND OTHER		
Mission Management	0	165,144
Mission Management	0	55,608
UBS Paine Webber	20,800	0
State of Israel	16,840	15,641
AT&T	0	105,750
Money Market	4,049	4,312
TOTAL BONDS AND OTHER	41,689	346,455
GRAND TOTAL	$79,179,318	$83,400,470

Exhibit F
Form 990
Part IV Line 56

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
SCHEDULE OF INVESTMENTS - OTHER

	3/31/2004	3/31/2005
U.S. Treasury Notes	$77,403,635	$87,166,757

Exhibit G
Form 990
Part VI Line 90a

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
STATES WHICH WILL RECEIVE COPY OF THIS RETURN
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

Alabama
Arkansas
Arizona
California
Connecticut
Florida
Georgia
Illinois
Indiana
Kansas
Kentucky
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
New Hampshire
New Jersey
New Mexico
New York
North Carolina
Ohio
Oklahoma
Oregon
Pennsylvania
South Carolina
Tennessee
Utah
Washington
West Virginia
Wisconsin

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
RESEARCH
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

General

The Muscular Dystrophy Association, Inc., (MDA) is a not-for-profit corporation incorporated on June 6, 1950, under the laws of the State of New York. MDA supports worldwide research to find the causes of and cures for muscular dystrophy and related neuromuscular disorders. The programs of MDA are supported almost entirely by individual private contributions from the general public. MDA neither receives fees from those it serves nor applies any means test for services, and by choice is not a United Way-supported agency.

The diseases supported by MDA are the muscular dystrophies (among which are Duchenne and Becker); motor neuron diseases (including amyotrophic lateral sclerosis (Lou Gehrig's disease) and spinal muscular atrophy); the peripheral nerve disorders Charcot-Marie-Tooth disease and Friedreich's ataxia; inflammatory myopathies; disorders of the neuromuscular junction; metabolic diseases of muscle as well as other myopathies. Some of the over 40 neuromuscular diseases covered by MDA are fatal, while others result in chronic mobility impairment.

As reported by the U.S. Department of Health and Human Services, National Institutes of Health (NIH) , in the United States alone, muscular dystrophy and other neuromuscular disorders are estimated to affect some 1 million people.

Research

MDA sponsors research grants in the United States and 19 foreign countries. The Association's research program accounted for some $34.3 million of its expenditures for the fiscal year. MDA's Scientific and Medical Advisory Committees, whose members are among the nation's foremost scientists and physicians in the field of neuromuscular disease, carefully review all research supported by the Association. MDA maintains a diverse program of basic research which advances investigations of possible treatments for neuromuscular diseases, muscle function, regulation and regeneration; biochemical changes involved in muscle disease; the genetics of neuromuscular disease; and the interaction of nerve and muscle. This work is necessary in order to provide a sound scientific foundation from which practical advances against disease can arise. Additionally, the Association's recently established Translational Research Advisory Committee (TRAC) is focused on milestone driven contracts with the biotech industry, pharmaceutical companies and academic investigators for research that is directly relevant to bringing new therapies to market. Members of TRAC include a number of top neuromuscular disease researchers, as well as representatives of NIH and industry. Among the first assignments of TRAC was to develop a strategic plan for research priorities.

Searching for the Causes of Neuromuscular Disease

The majority of the neuromuscular diseases, including all of the muscular dystrophies, covered by MDA programs are genetic disorders. In 1986, MDA researchers ushered in a new era in neuromuscular disease research with the identification of the gene that when defective causes Duchenne and Becker muscular dystrophies. This gene, identified as the largest human gene ever discovered was the first major human disease gene isolated without prior knowledge of its protein product. MDA has been in the forefront of research on inherited diseases with an ever-expanding list of new genetic research projects and an extensive list of genes that have been found defective in inherited neuromuscular disorders.

MDA-funded scientists continue to investigate the causes of muscle disease. Other Association-supported researchers are focusing on the body's immune system. Several neuromuscular diseases, such as myasthenia gravis, polymyositis and dermatomyositis are known to involve an abnormal immune system attack on muscle or nerve. In addition, amyotrophic lateral sclerosis may result from excitotoxic or oxidative injury to motor neurons and MDA scientists are studying these disease mechanisms in the hope of finding possible modes of treatment. Findings from early research supported by MDA served as the scientific basis for approval by the FDA of the first drug available for prescription use for ALS. This drug, called riluzole, works by partially blocking the natural substance glutamate. MDA researchers worked on the glutamate theory that led to riluzole's development. Based on this theory MDA-supported scientists have been testing other drugs that block glutamate.

Search for Treatment

A number of measures have been adopted to treat neuromuscular diseases including, nutrition, bracing, physical therapy and drugs such as prednisone. Several measures are used to successfully manage these disorders. Plasma exchange is a life saving measure for myasthenia gravis, prednisone slows the progression of muscle weakness in Duchenne muscular dystrophy (DMD) and L-carnitine is used in the treatment of carnitine deficiency.

A flaw within the cells of the body—the genes—causes the majority of the diseases MDA is striving to combat. MDA has advanced research directed at developing effective ways to treat muscular dystrophy by correcting the basic gene disturbance causing muscle weakness. This can be done through cell-based therapies. MDA researchers are using a variety of strategies to achieve this.

One potential treatment is to replace the missing or defective muscle proteins. This is the technique known as gene therapy. By inserting healthy genes into muscle cells, MDA-supported researchers have demonstrated in the laboratory that these genes can begin to produce the essential protein needed to develop healthy muscles. It is known with certainty that gene therapy can at least slow muscle destruction.

Another cutting-edge technology being applied to neuromuscular diseases is stem cell therapy. Stem cells are undeveloped cells that give rise to and assemble tissues and organs. Within the body millions of these cells are waiting to be called into action. MDA scientists have been able to encourage these undeveloped cells to form muscle and other tissue. The next step will be to insert stem cells into muscles weakened by muscular dystrophy and have them replace the damaged cells.

Another measure being developed to repair muscle cells is through gene correction. In the laboratory, scientists have been able to correct an improper message in the gene code that blocks the gene's ability to make a protein. A clinical trial in one method of gene correction is now underway and researchers are developing other methods with the hopes of applying the procedure to those affected by certain neuromuscular disorders.

MDA continues to strengthen its partnerships with industry and the NIH to advance therapies for neuromuscular disease. For example, MDA is partnering with Wyeth Pharmaceuticals (Collegeville, PA) through providing supplemental funding for a clinical trial of MYO-029, a compound that blocks myostatin, a natural protein that ordinarily inhibits the growth of muscles. Both MDA-funded investigations and Wyeth-conducted research have suggested that blocking myostatin's activities might improve muscle growth and survival and at least partially offset the muscle degeneration associated with certain disorders. MDA continues to fund research on the biological mechanisms underlying myostatin's effects. MDA continues its support of the clinical trial of a potential treatment of Pompe's disease sponsored by Genzyme Corporation. For example, Pompe's, a severe disease that is usually fatal in infants, is now being treated with great success in clinical trials. Research supported by MDA provided the scientific basis for a potential treatment for Pompe's. The expanded trials will include a larger population of those affected by Pompe's. Additionally, a study designed to observe the course of the disease in adults is underway. Some of the participants in that study will later have the opportunity to enroll in a late-onset treatment study in which they will receive the enzyme.

The Muscular Dystrophy Association will supplement funding from the NIH, a component of the Federal Department of Health and Human Services, for up to three muscular dystrophy cooperative research centers. This partnership between NIH and MDA is a critical step toward improving quality of life for those affected by muscular dystrophy. MDA's supplemental funding of the cooperative centers will provide the additional support essential to advancing highly focused muscular dystrophy research and training in medical management MDA is providing grant funding up to a maximum of $500,000 per center per year for three years.

MDA continues its support of the North Carolina biotechnology company Asklepios to develop gene therapy for DMD. Researchers at the Gene Therapy Center of the University of North Carolina at Chapel Hill and the Department of Molecular Genetics & Biochemistry at the University of Pittsburgh make up the research team. The company plans to develop and test a virus-based system designed to deliver a miniaturized

dystrophin gene to the muscles of boys with DMD. Dystrophin is the muscle protein missing in the disease.

Recent Research Accomplishments

MDA-funded research in 2004-2005 steadily built on earlier advances against a wide variety of muscle-wasting diseases. Progress was made at both the molecular level -- in decoding disease mechanisms -- and at the practical level, in identifying and testing promising treatments.

MDA continued its strategy of collaborating with researchers, physicians, government and businesses to fast-track promising research into lifesaving practical therapies. MDA grantees studying amyotrophic lateral sclerosis (ALS) identified potential drug treatments and uncovered new triggers and risk factors. Although the cause of the disease remains unknown in most cases, an MDA-supported research group concluded there is "biologic plausibility" that activation of dormant retroviruses in DNA could be a contributing factor. Possible ALS risk factors also were identified in variants in the genes for Hfe and peripherin.

MDA-supported researchers also identified the senataxin gene as one that, when flawed, causes a juvenile-onset form of ALS.

To gain further insight into the causes of ALS, MDA grantees launched a study of disease patterns and genetics, using interviews, questionnaires and blood samples. ALS mouse and human trials of various compounds yielded encouraging results. After finding that the compound sodium phenybutyrate prolonged the life of mice with ALS, a trial in humans was begun in conjunction with the Veterans Administration.

A clinical trial of the breast cancer drug tamoxifen showed it may prolong survival in people with ALS when given at certain dosages. A human trial is under consideration for the drug ceftriaxone after finding it extends life and prolongs strength in mice with ALS. MDA researchers followed up on their finding that a lack of vascular endothelial growth factor (VEGF) may contribute to ALS by demonstrating that delivering VEGF as a gene or protein benefits mice with ALS.

In DMD, the Recombinant DNA Advisory Committee of the NIH gave the green light to MDA-supported gene therapy researchers hoping to do human trials of a gene therapy compound for DMD. This approval was critical to the work of the biotechnology firm Asklepios, which is receiving funding from MDA to develop gene therapy strategies for DMD.

Also in the area of gene therapy, MDA awarded a $1.5 million grant to PTC Therapeutics, which is developing a drug (PTC124) that causes cells to "read through" a specific type of genetic error that affects approximately 15 percent of children with DMD. A phase 1 study showed the compound is safe and reached adequate blood levels in healthy volunteers. The next step is testing the drug in boys with DMD with the specific genetic flaw.

A subcommittee of the American Academy of Neurology (AAN), composed primarily of MDA clinic directors and research grantees, released a practice guideline for physicians treating children with DMD, outlining the most effective way to use the steroid prednisone to prolong muscle strength.

In researching treatments for spinal muscular atrophy (SMA), an MDA-backed researcher found that drugs known as aminoglycosides help cells produce more of the protein which is necessary for nerve cells to survive and function.

People with facioscapulohumeral, Becker and limb-girdle muscular dystrophies were enrolled in a trial of the drug MYO-029 developed by Wyeth Parmaceuticals.

MDA continues to build upon and expand research programs in a number of fronts and seeks to create new and innovative research opportunities.

MUSCULAR DYSTROPHY ASSOCIATION
#13-1665552
PATIENT AND COMMUNITY SERVICES
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

Throughout the United States and Puerto Rico, the Muscular Dystrophy Association, Inc. (MDA) provides a wide variety of services to those affected by any of the disorders in its program, irrespective of age, race, creed, color or sex. MDA's services program is designed to assist those affected by muscular dystrophy and related diseases of the neuromuscular system, which affect children as well as adults. A complete list of diseases covered by MDA is contained in the Association's services brochure, copies of which are available upon request through MDA's National Headquarters at 3300 East Sunrise Drive, Tucson, Arizona 85718, from any of its 230 field offices in the United States and Puerto Rico, or its Web site at *www.mdausa.org*.

MDA maintains the most comprehensive services program of any voluntary health agency in the country, helping individuals and their families meet the problems imposed by chronic, progressive neuromuscular diseases. This aspect of the Association's program accounted for over $79.2 million of its expenditures for fiscal 2005. The Association makes available a broad program of services ranging from a nationwide network of clinics providing access to top health professionals skilled in the diagnosis and medical management of neuromuscular diseases to assistance with essential support services. In this connection, MDA offers the following to benefit individuals affected by neuromuscular diseases:

- Diagnostic consultations and follow-up examinations by neuromuscular specialists through a nationwide network of over 235 MDA clinics (see Exhibit L attached)
- Genetic counseling services through MDA clinics
- Assistance with the purchase and repair of wheelchairs to maintain independence and mobility
- Assistance with the purchase and repair of leg braces
- Assistance with the purchase of communication devices
- Durable medical equipment loan programs through which individuals can receive walkers, hospital beds, bath aids or other items to enhance independence
- 90 week-long camp programs for young people affected by neuromuscular disease

- Assistance with transportation for MDA clinic appointments and MDA summer camp
- Annual physical, occupational, respiratory and speech therapy consultations
- Educational seminars that provide information about neuromuscular diseases and offer a forum to discuss subjects of importance to families living with these disorders
- Support groups to assist families and individuals in dealing with the special problems imposed by neuromuscular diseases

MDA Clinics

MDA maintains a network of over 235 hospital-affiliated neuromuscular clinics located at prestigious medical institutions and university-based facilities across the United States. At MDA clinics people with neuromuscular diseases have access to the nation's top specialists in this group of diseases. These clinics are essential to the medical management of neuromuscular diseases but are also key to the development of new therapies.

Each year MDA provides tens of thousands of medical visits through its clinic program. Individuals affected by any of the disorders in MDA's purview have access to these hospital-affiliated and university-based clinics staffed by top health professionals using a multidisciplinary team approach. These experts advise about all aspects of medical management of neuromuscular disease, including respiratory care and physical therapy. Anyone whose physician suspects a neuromuscular disorder, upon referral by the person's physician, would be eligible for a diagnostic evaluation at an MDA clinic. Should the diagnosis indicate a disease other than one included in MDA's program, the Association will then refer the individual to an appropriate community resource.

Also, MDA clinics are essential to the advancement of neuromuscular disease research. They serve as the key centers for ongoing clinical trials for the development of a wide range of potential therapies. The Association's research priority is the support of projects that focus on the development of therapies. MDA clinics are the focal points for the clinical application of scientific advances designed to treat neuromuscular diseases.

MDA/ALS Clinical Research Centers

The Association has established 34 regional amyotrophic lateral sclerosis (ALS) research and clinical centers across the country to focus attention on a very rapidly progressive debilitating neuromuscular disorder that strikes adults in the prime of life.

They are:

- The Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University Medical Center in New York;
- Forbes Norris MDA/ALS Research Center at California Pacific Medical Center in San Francisco;
- Jerry Lewis MDA/ALS Clinical and Research Center at the University of Southern California in Los Angeles;
- MDA/ALS Clinical Research Center at the University of Wisconsin in Madison;
- The Vicki Appel MDA/ALS Center at Methodist Hospital in Houston;
- MDA/ALS Center at Massachusetts General Hospital in Boston;
- MDA/ALS Research Center at the University of Chicago Hospitals in Chicago;
- MDA/ALS Center at UCLA in Los Angeles;
- MDA/ALS Center at the University of Colorado in Denver;
- MDA/ALS Center at Yale University in New Haven, Connecticut;
- MDA/ALS Center at Emory University School of Medicine in Atlanta;
- MDA/ALS Center at Johns Hopkins University in Baltimore;
- MDA/ALS Center at Washington University School of Medicine in St. Louis;
- MDA/ALS Center at Duke University in Durham, N.C.;
- MDA/ALS Center at the University of Texas in Dallas;
- Kessenich Family MDA/ALS Center at the University of Miami;
- MDA/ALS Center at the University of Utah in Salt Lake City;

- MDA/ALS Center at Carolinas Medical Center in Charlotte;
- MDA/ALS Center at SUNY Health Sciences Center - Syracuse;
- MDA/ALS Center at the University of Kansas Medical Center in Kansas City, Kansas;
- MDA/ALS Center at Mt. Sinai Hospital and Medical Center in New York;
- MDA/ALS Center of Hope at Drexel University College of Medicine in Philadelphia;
- MDA/ALS Center at St. Joseph's Hospital and Medical Center in Phoenix, AZ;
- MDA/ALS Center at the University of Arizona Health Sciences Center in Tucson, AZ;
- MDA/ALS Center at the University of New Mexico Health Sciences Center in Albuquerque;
- MDA/ALS Center at the University of California, Irvine in California;
- MDA/ALS Center through the University of Texas Health Science Center at San Antonio, TX;
- MDA/ALS Center at the University of Washington Medical Center, Seattle, WA;
- MDA/ALS Center at Vanderbilt University Medical Center, Nashville, TN;
- MDA/ALS Center at Ohio State University, Columbus, OH;
- MDA/ALS Center at the University of Rochester Medical Center in Rochester, NY;
- MDA/ALS Center at the University of Arkansas for Medical Sciences in Little Rock;
- MDA/ALS Center at the University of Pittsburgh Medical Center in Pittsburgh;
- MDA/ ALS Center at the University of Massachusetts Medical Center in Worcester.

MDA's services program is administered through its network of some 230 field offices located in the United States and Puerto Rico. MDA Health Care Service Coordinators knowledgeable about federal, state and local community resources also assist hundreds of thousands of people with disabilities and their families by advising them about other services for which they may be eligible.

Thousands of people benefit each year from MDA's assistance with durable medical equipment. For example, in fiscal 2005 MDA assisted with the purchase of wheelchairs, leg braces and communication devices. The Association also augmented payment for wheelchair and leg brace repairs. In addition, thousands of adaptive devices were provided to individuals through MDA's local equipment loan closet programs -- including, but not limited to, walkers, canes, bath equipment, wheelchairs, hydraulic lifts and hospital beds.

In fiscal 2005 some 4,100 young people enjoyed a week of fun and friendship through MDA summer camps which offer activities geared to the special needs and abilities of those with neuromuscular disease. Thousands of individuals and their families received support through MDA's nationwide network of 290 support groups, as well as through MDA-sponsored educational seminars, referral services and online chat sessions at *www.mdausa.org/chat/calendar.html*.

MDA makes available many informational videos that address the special medical needs of those with neuromuscular diseases. For those whose breathing is compromised, a 25-minute video on respiratory assistance is available at no cost. Also available for newly-diagnosed families is a 15-minute video entitled "The MDA Support Group and You," which is designed to dispel doubts and highlight benefits of attending support groups. For parents of boys affected by Duchenne muscular dystrophy (DMD), a 39-minute video titled "Standing and Walking are Gifts: A Guide to Heel Cord Tenotomy" provides an overview of the surgical procedure often recommended for prolonging walking in boys affected by the disorder.

A vast array of publications are also available that address a variety of medical concerns such as nutrition, mobility and problems relating to chewing and swallowing. Materials are also available to help parents and caregivers of those affected by neuromuscular disease. Specialists in the various medical disciplines addressed by these materials served as editorial advisors and contributing editors.

Additional information about MDA's Health Care and Community Services Program is available through MDA's Web site at *www.mdausa.org/clinics/*.

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
PROFESSIONAL AND PUBLIC HEALTH EDUCATION
FOR THE FISCAL YEAR ENDING MARCH 31, 2005

In the fiscal year ended March 31, 2005, the Muscular Dystrophy Association (MDA) expended $20.8 million on its professional and public health education program. MDA's public information and health education program seeks to meet the needs of the medical profession, the scientific community, the general public and people with neuromuscular diseases by providing timely and thorough information about MDA's programs and the diseases they cover.

MDA produced, updated and distributed dozens of publications to millions of people describing the Association's comprehensive services, its extensive research program and the more than 40 neuromuscular disorders that MDA covers, and providing advice to families affected by neuromuscular diseases. The Public Information Department produced six issues of MDA's award-winning bimonthly national magazine, Quest, offering a readership of more than 350,000 a stimulating mix of articles. These articles touched on a range of diseases in MDA's program, and highlighted progress being made by MDA-supported researchers, MDA services, health care information, and assistance with disability-related issues affecting individuals and families. In addition, MDA's TV Production Department produced and distributed educational videos on various topics for families affected by neuromuscular diseases.

MDA also produced its monthly ALS Newsmagazine for those affected by Lou Gehrig's disease. MDA created several new brochures in its "Facts About" series providing basic information about individual diseases in MDA's program, geared toward people newly diagnosed, and revised and reprinted several other disease-specific publications for those affected and their families. The Association also developed a new publication for families living with ALS titled Everyday Life With ALS: A Practical Guide.

Tens of thousands of print public services advertisements carried the MDA message in newspapers and other periodicals across the country, with circulation in the tens of millions. Many millions more saw television public service announcements on local and national broadcast networks of all types, including cable channels. News about MDA activities and research advances was carried by major wire services, on television news programs and in thousands of newspaper and magazine articles.

The Association made its complete range of literature available electronically on its three main Web sites: www.mdausa.org, www.mdaenespanol.org and

www.als.mdausa.org. The Web sites offered a constant stream of updated information about MDA's programs. Internationally recognized as a key source of information about neuromuscular diseases, the main site attracted visitors from dozens of countries around the world. Total visits to the site amounted to more than 5.4 million for the year.

The Association conducted more than 100 sessions per month of its popular online chats. Visitors to the MDA sites also had the opportunity to ask questions about diseases, research and services and many other topics.

Health professionals obtained the latest information about neuromuscular disease through the Association's library of print materials and its expansive Web site – which includes an "Ask the Experts" feature where questions are answered by researchers and clinicians who specialize in neuromuscular disease. Additional information was offered to the medical community through educational videos and community-based seminars offering updates on neuromuscular disease research. Secure online areas were also available for MDA scientific investigators and clinicians to exchange information and ideas.

MDA's e-mail newsletter, MDA e-update, delivered news about research breakthroughs and other pertinent information to friends of the Association. The online newsletter is distributed on a monthly basis to keep readers current on rapid research progress and other news from the Association.

Exhibit I
Form 990
Part V

MUSCULAR DYSTROPHY ASSOCIATION, INC.
OFFICERS (*) AND MEMBERS OF THE BOARD OF DIRECTORS
July 9, 2004

National Office
3300 East Sunrise Drive
Tucson, Arizona 85718-3208

Stanley H. Appel, M.D.

*Robert M. Bennett
Chairman of the Board

Louis R. Benzak

Jann T. Carl

Leon I. Charash, M.D.

Bart Conner

Harold C. Crump

Joseph S. DiMartino

R. Rodney Howell, M.D.

Dave Hutton

Suzanne Lowden

Jim Major

*Timmi Masters
Secretary

Maureen McGovern

Ed McMahon

*Olin F. Morris
Vice Chairman of the Executive Committee

Christopher J. Rosa, Ph.D.

*Robert Ross
President & CEO

John N. Tognino

*Lois R. West
Chairman of the Executive Committee
President Emeritus

*Victor R. Wright
Treasurer

OTHER OFFICERS
Gerald C. Weinberg
Senior Vice President

Daniel Bereck
Assistant Treasurer

Stephen P. Evans
Assistant Treasurer

Christina C. Kennedy
Assistant Secretary

Gail Schmertz Kerner, Esq
Assistant Secretary

Exhibit J
Form 990
Schedule A
Part III Line 3a

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
STATEMENTS ABOUT ACTIVITIES
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

The Association awards research grants each year to physicians and scientists in the United States and abroad where research is directed toward developing effective treatments for the neuromuscular disorders covered by the Association's programs.

The determination for the award of research grants is based on a review of formal proposals submitted by applicants. These proposals include detailed descriptions of the program to be funded and supporting documents detailing the credentials and professional accomplishments of the applicant.

This information is reviewed by members of one of the following:

1. Scientific Advisory Committee
2. Medical Advisory Committee

The determination is made based on scientific merit and relevance to stated purposes of the Association. Awards are authorized by the Board of Directors for a period of one to three years. The Association records the initial year's liability and related expense for these grants after they have been recommended for approval by the Association's Scientific or Medical Advisory Committees and approved by the Board of Directors. Funding of the remaining committed future amounts of grants is contingent upon satisfactory scientific and medical review and the availability of funds. Research grant funds are generally transmitted to the appropriate financial officer of the grantee institution.

Exhibit K
Form 990
Part II Line 23

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

	Aggregate Charges	Third Party Reimbursements	Net	
Clinic program	$7,059,768	$0	$7,059,768	
Orthopedic equipment & repairs	7,505,845	(1,535,506)	5,970,339	
Summer camp program	2,611,226	0	2,611,226	
Other	848,746	(10,274)	838,472	
Specific assistance	$18,025,585	($1,545,780)	$16,479,805	Part II Line 23
Other Patient & Community Services related expenses			62,751,320	
			$79,231,125	Part IIIb

Directory of MDA Clinics

*(*MDA/ALS Center Directors)*
(Effective as of June 2005)

ALABAMA

BIRMINGHAM
The Children's Hospital
Director.
Charles R Law, M D

University of Alabama Hospital
Codirectors
Shin J Oh, M.D.
Gwendolyn C. Claussen, M D

HUNTSVILLE
Huntsville Hospital
Codirectors·
Tejanand G. Mulpur, M D.
Anjaneyulu Alapati, M D

MOBILE
Rotary Rehabilitation Hospital
Director:
John G Yager, M D , Ph D.

MONTGOMERY
Baptist Medical Center
Codirectors
Joseph Leuschke, M.D
Leah O Sanchez, M.D.

ALASKA

ANCHORAGE
Alaska Regional Hospital
Director·
Michel Gevaert, M D

ARIZONA

PHOENIX
St Joseph's Hospital and Medical Center
Codirectors:
John Bodensteiner, M.D
Richard Stanley Burns, M D*

TUCSON
The Mucio F. Delgado Clinic for Neuromuscular Disorders,
University of Arizona Health Sciences Center
Director·
Lawrence Z. Stern, M D*

ARKANSAS

FORT SMITH
Cooper Clinic
Codirectors·
James H. Buie, M D.
William A Knubley, M D.

LITTLE ROCK
University of Arkansas for Medical Sciences Ambulatory Care Center
Director·
Stacy A. Rudnicki, M.D.*

CALIFORNIA

BAKERSFIELD
Mercy Hospital

DOWNEY
Rancho Los Amigos National Rehabilitation Center
Director.
Irene S Gilgoff, M D.

FRESNO
MD Medical Group
Director·
Abbas Mehdi, M D

LOMA LINDA
Loma Linda University Medical Center
Codirectors
Stephen Ashwal, M.D.
James E Shook, M.D.
Laura Dawn Hen Nist, M D

LOS ANGELES
University of California at Los Angeles
Codirectors.
Thomas L Anderson, M D
Michael C Graves, M D*

The Hospital of the Good Samaritan/
University of Southern California
Neuromuscular Center
Codirectors:
Valerie Askanas, M.D
W. King Engel, M D*

MADERA
Valley Children's Hospital
Director
Amanda N Fernandez

ORANGE
Children's Hospital of Orange County
Director:
Samuel R Rosenfeld, M.D.

University of California, Irvine Medical Center
Codirectors·
Tahseen Mozaffar, M.D.*
John Weiss, M D*

SACRAMENTO
University of California at Davis Medical Center
Director
Craig McDonald, M D.

SAN DIEGO
Children's Hospital
Director
Paul Schultz, M D

SAN FRANCISCO
California Pacific Medical Center
Codirectors·
Deborah F. Gelinas, M D
Robert G. Miller, M D*

University of California at San Francisco Medical Center/UCSF Children's Hospital
Director·
Jonathan B. Strober, M D.

SANTA BARBARA
Santa Barbara Cottage Hospital
Director
David Frecker, M D

STANFORD
Stanford University
Codirectors.
Ching H. Wang, M D , Ph D.
Yuen Tat So, M D

COLORADO

DENVER
The Children's Hospital
Director:
Dennis J Matthews, M D

University of Colorado
Codirectors:
Hans E. Neville, M.D.*
Steven P. Ringel, M D.*

CONNECTICUT

FARMINGTON
University of Connecticut Health Center
Director
Kevin J Felice, D O.

HARTFORD
Connecticut Children's Medical Center
Codirectors·
Carol R Leicher, M D.
Brian G Smith, M.D

NEW HAVEN
Yale University
Director
Jonathan M Goldstein, M D*

DELAWARE

WILMINGTON
Alfred I DuPont Hospital for Children
Codirectors:
Mena Scavina, D O.
Laura S Inselman, M.D.
William G. Mackenzie, M D.

Christiana Care Health Services
Director.
Charles Bean, M D

DISTRICT OF COLUMBIA

WASHINGTON
Children's Hospital National Medical Center
Codirectors.
Sarah H, Evans, M.D.
Diana Escolar, M D

Georgetown University Hospital
Director
Michael Sirdofsky, M.D

FLORIDA

FT. LAUDERDALE
Broward General Medical Center
Director.
Harish D. Thaker, M.D.

FT. MYERS
Lee Memorial Hospital
Director:
Harris L Bonnette, M.D.

GAINESVILLE
University of Florida Clinic in the UF Health Sciences Center at Shands Hospital
Director:
Edward Valenstein, M D

JACKSONVILLE
Mayo Clinic Jacksonville
Director:
Kevin B. Boylan, M D

Nemours Children's Clinic at Jacksonville
Director
David N Hammond, M.D.

MIAMI
University of Miami School of Medicine
Director
Walter G Bradley, D M , FR C.P.*

ORLANDO
Orlando Regional Lucerne Hospital
Director
Michael J Creamer, D.O

Nemours Children's Clinic at Orlando
Director·
Michael Pollack, M D

PANAMA CITY
HealthSouth Lisenby Clinic
Director·
Jack B Shumate, M D

SARASOTA
HealthSouth Outpatient Rehabilitation &
Sports Medicine Center
Director
J. Terry Petrella, M D

ST. PETERSBURG
St. Petersburg Neurology Clinic
Director:
Allan S Weiss, M D

TALLAHASSEE
Tallahassee Neurological Clinic
Codirectors.
Ricardo Ayala, M D
Winston R. Ortiz, M.D.

TAMPA
Tampa Children's Hospital at St. Joseph's
Director
Raymond J Fernandez, M D

WEST PALM BEACH
St. Mary's Hospital
Director.
S. Russell Wilson, M D

GEORGIA

ATLANTA
Emory University Center for Rehabilitation
Medicine
Codirectors.
Linton Cooke Hopkins, M D
Michael Benatar, M.D., Ph D.
Jonathan D Glass, M D*

Children's Health Care of Atlanta
Codirectors.
Edward Goldstein, M D
Joanne Janas, M D

AUGUSTA
Medical College of Georgia
Director.
Jerry Ned Pruitt II, M.D

WARM SPRINGS
Roosevelt Institute for Rehabilitation

HAWAII

KAILUA
Castle Medical Center
Codirectors·
Ronald Yamaoka, M D
Kevin G Kimata, M D

IDAHO

BOISE
Idaho Elks Rehabilitation Hospital
Director
Robert H. Friedman, M.D.

ILLINOIS

CHICAGO
Northwestern Memorial Hospital
Codirectors
Teepu Siddique, M D
Robert Sufit, M.D

Rush University Medical Center
Codirectors
Peter Thomas Heydemann, M D
Irwin M Siegel, M.D

University of Chicago Hospitals
Codirectors
E Chelmicka-Schorr, M D
Raymond Roos, M.D.*
Betty C. Soliven, M D

University of Illinois at Chicago
Director
Julie Rowin, M D

EAST MOLINE
Trinity Outpatient Rehabilitation Center
Codirectors.
Kazi Imran Majeed, M D.
Vardges Vandian, D O
Miguel A. Sanguino, M D

EVANSTON
Evanston Hospital
Director:
David Randall, D O

HINSDALE
Hinsdale Hospital
Director
Thomas D Sullivan, M D

PEORIA
OSF Saint Francis Medical Group Center
Codirectors
Jai Kumar, M D
Greg Blume, M.D.
Christopher M. Zallek, M.D.

SPRINGFIELD
Memorial Medical Center
Director.
Michael R Pranzatelli, M.D.

Saint John Rehabilitation
Director
Rodger J Elble, M D , Ph D

URBANA
Carle Clinic Association
Director.
Robert Cranston, M D.

INDIANA

ELKHART
Elkhart Clinic, LLC
Director·
Thomas R. Vidic, M.D.

EVANSVILLE
St. Mary's Medical Center
Director
Raymond Nicholson Jr., M.D

FORT WAYNE
Lutheran Hospital
Codirectors·
Jerry L Mackel, M.D.
C.J Ottinger, M D

INDIANAPOLIS
Indiana University Hospital
Director·
Robert Pascuzzi, M D

Methodist Hospital of Indiana
Director.
James Pappas, M D

IOWA

DES MOINES
Younker Memorial Rehabilitation Center
Director
Calvin Jay Hansen, M D

IOWA CITY
University of Iowa Hospitals and Clinics
Director
Katherine Mathews, M.D.

KANSAS

KANSAS CITY
University of Kansas Medical Center
Codirectors·
John B Redford, M D.
Arthur Dick, M D*

WICHITA
Via Christi Medical Center — St. Francis
Campus
Director
Dilawer H. Abbas, M.D.

KENTUCKY

LEXINGTON
University of Kentucky Medical Center
Director·
Arman Sabet, M.D

LOUISVILLE
Baptist Hospital East
Director:
Gregory L. Pittman, M D.

LOUISIANA

ALEXANDRIA
Rapides Regional Medical Center
Director:
Charles Ugokwe, M D , MPHTM

BATON ROUGE
The NeuroMedical Center
Director.
Oscar Leslie Rogers III, M D , Ph D

The Baton Rouge Clinic, AMC
Director.
Barbara Jean Golden, M.D.

LAFAYETTE
Our Lady of Lourdes Hospital

MONROE
St. Francis Medical Center
Codirectors·
Aristoteles Pena-Miches, M.D.
Arun Kalra, M.D.

NEW ORLEANS
Louisiana State University Medical Center
Director·
Amparo Gutierrez, M D.

Children's Hospital
Codirectors.

Ann Henderson Tilton, M.D
Joaquin Wong, M D.
Maria Weimer, M D.

SHREVEPORT
Louisiana State University Health Science Center
Director·
Robert N. Schwendimann, M D

MAINE

BANGOR
Eastern Maine Medical Center
Codirectors
R Stephen S. Amato, M.D., Ph D
Peter Keebler, M D.

PORTLAND
Maine Medical Center
Director·
Stephen D Rioux, M D.

MARYLAND

BALTIMORE
Johns Hopkins University
Codirectors.
Daniel B Drachman, M D
Jeffrey D Rothstein, M D, Ph D*
Thomas O Crawford M.D
Kathryn Wagner, Ph.D.

Maryland General Hospital
Director
Neil C. Porter, M.D

MASSACHUSETTS

BOSTON
Brigham and Women's Hospital
Director·
Anthony A. Amato, M.D.

Children's Hospital Corporation
Codirectors·
Fred Shapiro, M D.
Basil Darras, M D

Massachusetts General Hospital
Director
Robert H Brown, M D, Ph.D*

New England Medical Center Hospital
Director
Harry C Webster, M D

BURLINGTON
Lahey Clinic Foundation
Codirectors.
H Royden Jones, M D.
James A. Russell, D.O.

SPRINGFIELD
Baystate Medical Center
Director
George Baquis, M D.

WORCESTER
University of Massachusetts Medical Center
Director
David Chad, M.D.*

MICHIGAN

DETROIT
Children's Hospital of Michigan
Codirectors·
Michael A. Nigro, D O.
A Edward Dabrowski, M D
Gyula Acsadi, M D, Ph.D

Wayne State University Physician Group
Adult MDA Clinic at Harper University Hospital
Codirectors·
Michael Shy, M D
Richard A Lewis, M.D

EAST LANSING
Michigan State University Clinical Center
Director:
David Simpson, D O

FARMINGTON HILLS
Michigan Institute for Neurological Disorders
Codirectors·
Michael A. Nigro, D O
Louis Rentz, D.O
David A. Simpson, D O.

FLINT
McLaren Regional Medical Center
Codirectors
Ronald Hunt, M D
David A Green, M D

GRAND RAPIDS
Mary Free Bed Hospital
Director
John F Butzer, M.D.

KALAMAZOO
Kalamazoo Center for Medical Studies at Michigan State University
Codirectors:
Daniel Fain, M D
Michelle Crooks, M D

MARQUETTE
Marquette General Hospital
Director.
Frederick Maynard Jr, M D.

MIDLAND
MidMichigan Medical Center
Director
Kamal Sadjadpour, M D

MINNESOTA

DULUTH
The Duluth Clinic
Director
Wolcott S Holt, M D.

MINNEAPOLIS
Fairview University Medical Center
Director
John West Day, M D, Ph.D

ROCHESTER
Mayo Clinic
Director.
Eric J Sorenson, M D

MISSISSIPPI

JACKSON
University of Mississippi Medical Center
Director.
S H. Subramony, M.D

OCEAN SPRINGS
Gulf Coast Neurology Center
Codirectors·
Lennon E. Bowen IV, M D.
William Evans, M.D
Michael Winkelmann, M D.

MISSOURI

CAPE GIRARDEAU
Southeast Outpatient Rehabilitation
Director
Paul J Guidos, M D

COLUMBIA
University Hospital/
Rusk Rehabilitation Center
Director·
Upinder K Dhand, M.D.

JOPLIN
St. John's Regional Medical Center
Director.
Waqar Waheed, M.D.

SPRINGFIELD
St. John's Regional Health Center
Codirectors:
Michael Luzecky, M D
Rodney Quinn, M D.
George F. Wong III, M D
Steven M Otto, M.D.

ST. LOUIS
Washington University School of Medicine
Director.
Alan Pestronk, M D*

MONTANA

BILLINGS
Deaconess Billings Clinic
Codirectors.
Mary Gaddy, M D.
Bill S. Rosen, M.D.

GREAT FALLS
Benefis Therapy Center
Director
William E Henning, D O

MISSOULA
Community Medical Center
Director
William E Henning, D O.

NEBRASKA

OMAHA
University of Nebraska Medical Center
Codirectors.
Gary Pattee, M D.
Wayne Stuberg, Ph D, PT

NEVADA

LAS VEGAS
UMC Enterprise Quick Care
Codirectors:
Donald William Johns, M.D
David L. Ginsburg, M.D.

RENO
Washoe Medical Center — South Meadows
Director
Timothy Louie, M D.

NEW HAMPSHIRE

LEBANON
Mary Hitchcock Memorial Hospital
Codirectors:
Nancy Bagley, M.D
Brian D Kossak, M.D.

NEW JERSEY

EDISON
John F Kennedy Medical Center
Director:
Thomas E. Strax, M.D.

ENGLEWOOD
Englewood Hospital
Codirectors:
Stanley J. Myers, M.D.
Joseph H. Willner, M.D.
Harvey R. Gross, M.D.

NEWARK
UMDNJ — University Hospital
Codirectors:
Jennifer Michaels, M.D.
John Bach, M.D.

STRATFORD
Kennedy Memorial Hospital
Director:
Donald A. Barone, D.O.

TINTON FALLS
MDA Clinic and Neuromuscular Center at HealthSouth Rehabilitation Hospital of Tinton Falls
Codirectors:
Christos P. Anayiotos, M.D.
Judith F. Topilow, M.D.

TRENTON
St. Francis Medical Center
Director
Albert Tahmoush, M.D.

NEW MEXICO

ALBUQUERQUE
University of New Mexico Health Science Center
Director:
John E. Chapin, M.D.*

University of New Mexico Carrie Tingley Hospital
Director:
Leslie Morrison, M.D.

NEW YORK

ALBANY
Albany Medical Center Hospital
Director:
Neil Lava, M.D.

AMHERST
Dent Neurologic Institute
Director
Tomas Holmlund, M.D.

BRONX
Montefiore Medical Center
Director,
Alfred J. Spiro, M.D.

BROOKLYN
Long Island College Hospital
Director:
Gary Sclar, M.D., Ph.D.

BUFFALO
Erie County Medical Center
Director
Richard B.T. Cowan, M.D.

EAST MEADOW
Nassau University Medical Center
Codirectors:
Imran Wahedna, M.D.
Satish Kadakia, M.D.

NEW YORK
Hospital for Joint Diseases and Medical Center
Codirectors:
Alfred D. Grant, M.D.
Mary Lynn Chu, M.D.

Institute of Rehabilitation Medicine, New York University Medical Center
Codirectors
Jeffrey M. Cohen, M.D.
Mary Lynn Chu, M.D.

Mount Sinai Hospital and Medical Center
Codirectors.
Mark Sivak, M.D.
C. Warren Olanow, M.D., F.R.C.P.*
Dale J. Lange, M.D.*

Columbia University Medical Center
Codirectors.
Hiroshi Mitsumoto, M.D.*
Paul H. Gordon, M.D.*
Michio Hirano, M.D.
Darryl DeVivo, M.D.
Petra Kaufmann, M.D.

PORT JEFFERSON
St. Charles Hospital and Rehabilitation Center
Director
Scott McWilliams, M.D.

ROCHESTER
University of Rochester Medical Center/ Strong Memorial Hospital
Codirectors:
Charles A. Thornton, M.D.*
Rabi Tawil, M.D.

SYRACUSE
SUNY Upstate Medical University
Codirectors:
Carl J. Crosley, M.D.
Jeremy M. Shefner, M.D., Ph.D.*

UTICA
St. Luke's Memorial Hospital Center
Director
Carl J. Crosley, M.D.

WATERTOWN
Mercy of Northern New York
Director:
Carl J. Crosley, M.D.

WEST HAVERSTRAW
Helen Hayes Hospital
Director
Inocencia Carrano, M.D.

WHITE PLAINS
White Plains Hospital and Medical Center
Director,
Stanley B. Holstein, M.D.

NORTH CAROLINA

ASHEVILLE
Mission Hospital OccuMed
Codirectors:
Duff A. Rardin, M.D.
Michael H. Young, M.D.

CHAPEL HILL
University of North Carolina Hospitals
Codirectors.
Colin D. Hall, M.D.
James F. Howard Jr., M.D.

CHARLOTTE
Carolinas Medical Center
Director:
Jeffrey Rosenfeld, Ph.D., M.D.*

DURHAM
Duke University Medical Center
Codirectors
Donald B. Sanders, M.D.
E. Wayne Massey, M.D.
Richard S. Bedlack Jr., M.D.*

WILMINGTON
Wilmington Health Associates Medical Clinic, PLLC
Director
S. Susan Torres, M.D.

WINSTON-SALEM
Wake Forest University School of Medicine
Director
James B. Caress, M.D.

NORTH DAKOTA

FARGO
MeritCare Hospital
Codirectors.
Richard Craig Bailly, M.D.
Karen Reinke Garnaas, M.D.
Samira H. El-Zind, M.D.

OHIO

CINCINNATI
University of Cincinnati Medical Center
Director:
John Quinlan, M.D.

Children's Hospital Medical Center
Director.
Brenda Wong, M.D., M.R.C.P.

CLEVELAND
MetroHealth Medical Center
Codirectors:
Irwin B. Jacobs, M.D.
Marc David Winkelman, M.D.

COLUMBUS
Ohio State University Hospital
Codirectors.
Jerry Mendell, M.D.
John T. Kissel, M.D.*
Steven Nash, M.D.*

Children's Hospital Outpatient Care Center
Codirectors:
Jerry Mendell, M.D.
John T. Kissel, M.D.

TOLEDO
Center for Health Services
Director:
James A. Auberle, M.D.

YOUNGSTOWN
Dean Martin Neuromuscular Clinic/ St. Elizabeth Medical Center
Codirectors
Donald J. Tamulonis Jr., M.D.
John R. Becker, M.D.

OKLAHOMA

OKLAHOMA CITY
Integris Southwest Medical Center
Codirectors
Brent Beson, M.D.
Julie Parke, M.D.

TULSA
Children's Medical Center
Director:
G. Steve Miller, M.D.

OREGON

EUGENE
Sacred Heart Hospital
Director:
Steven Goins, M D

MEDFORD
Providence Medford Medical Center
Codirectors.
Larry Maukonen, M D
Cornelia Byers, M D

PORTLAND
Oregon Health Sciences University
Codirectors
Barry S. Russman, M.D.
Jau-Shin Lou, M D., Ph.D.

Shriners Hospital for Children
Codirectors·
Barry S Russman, M D
Michael D Sussman, M D

PENNSYLVANIA

ALLENTOWN
Good Shepherd Rehabilitation Hospital
Director
Terry D. Heiman-Patterson, M D

DANVILLE
Geisinger Medical Center
Director·
Scott Mitchell Friedenberg, M D.

DUBOIS
DuBois Regional Medical Center
Director
Ruediger Kratz, M D

ERIE
Northshore Clinical Associates
Director
Jeffrey J Esper, D O

HERSHEY
Hershey Medical Center
Director
Zachary Simmons, M D

PHILADELPHIA
Children's Hospital of Philadelphia
Codirectors
Richard S Finkel, M D
Gihan Tennekoon, M D

Hospital of the University of Pennsylvania
Director·
Shawn J Bird, M D.

Drexel University College of Medicine
Codirectors
Terry Heiman-Patterson, M D*
Anahita Deboo, M D

PITTSBURGH
Children's Hospital of Pittsburgh
Director:
Henry B Wessel, M.D.

University of Pittsburgh Medical Center
Falk Clinic
Director·
David Lacomis, M.D.*

SAYRE
Guthrie Clinic
Director.
Paul Buckthal, M.D.

WILKES-BARRE
Geisinger Wyoming Valley Medical Center
Director.
Scott Mitchell Friedenberg, M D

WILLIAMSPORT
Williamsport Hospital
Director:
Young W. Park, M D.

PUERTO RICO

HATO REY
Hospital Auxilio Mutuo
Director:
Edward Ramos, M D

MAYAGUEZ
Hospital Universitario Ramon Emeterio Betances
Director.
Alfredo Perez Canabal, M.D

PONCE
Ponce School of Medicine
Director.
Carlos Otero, M D

SAN JUAN
University of Puerto Rico Medical Sciences
School of Medicine
Director:
Jose R. Carlo, M D

RHODE ISLAND

PROVIDENCE
Rhode Island Hospital
Director
James Gilchrist, M.D

SOUTH CAROLINA

CHARLESTON
Medical University of South Carolina
Director:
Timothy D Carter, M D.

COLUMBIA
Palmetto Richland Memorial Hospital
Director.
Miroslav Cuturic, M D

SPARTANBURG
Spartanburg Neurological Services
Codirectors·
Robert A. Ringel, M D
Bogdan P Gheorghiu, M D

SOUTH DAKOTA

RAPID CITY
Black Hills Rehabilitation Hospital
Codirectors:
K Alan Kelts, M.D
Matthew E. Simmons, M D

SIOUX FALLS
Neurology Associates
Director.
K Gene Koob, M.D.

TENNESSEE

CHATTANOOGA
Chattanooga Neurology Associates
Director.
Hytham A. Kadrie, M.D., F.R.C.P.

JOHNSON CITY
Northside Hospital
Director
Stephen L. Wayne, M D.

KNOXVILLE
St. Mary's East Towne
Codirectors
Randall G Trudell, M.D
Kendrick K Henderson, M D.

MEMPHIS
Baptist Memorial Hospital
Director.
Tulio Bertorini, M.D.

NASHVILLE
Vanderbilt University Medical Center
Codirectors.
Gerald M. Fenichel, M D*
Jane E Howard, M D.*

TEXAS

AMARILLO
Baptist St. Anthony's Health System
Codirectors:
Michael G. Ryan, M.D.
Rush A. Snyder Jr, M D.

ARLINGTON
Neurology Associates of Arlington
Director
Robert E McMichael, M D

BEAUMONT
HealthSouth Rehabilitation Center
Director:
Itzel S. Solis, M D

CORPUS CHRISTI
Spohn Hospital
Director
David A McFarling, M D.

DALLAS
University of Texas Health/Southwestern Medical Center
Codirectors.
Sharon Nations, M.D.
Jeffrey L. Elliott, M.D*
Gil I Wolfe, M D.
Susan Iannaconne, M D

Neurological Clinic of Texas
Director
Susan E. Hotz, M D

Texas Neurology, P.A.
Director.
Daragh Heitzman, M D.

DENISON
Texoma Neurology Associates
Director·
Easwar M Sundaram Jr., M D

EL PASO
Border Children's Health Center
Director
Johanan Levine, M D

FT. WORTH
Cook Children's Medical Center
Director·
Warren A. Marks, M.D

HARLINGEN
Valley Baptist Medical Center
Director.
Cynthia Anna Garcia, M.D

HOUSTON
Texas Children's Hospital
Codirectors.

Timothy Lotze, M.D.
Robert Cruse, D.O.

Texas Institute for Rehabilitation and Research
Director:
Itzel Solis, M.D.

The Vicki Appel MDA Neuromuscular Clinic
The Methodist Hospital
Codirectors.
Stanley H. Appel, M.D.*
Ericka P Simpson, M.D

LAREDO
Doctors Hospital of Laredo
Codirectors:
David A. McFarling, M.D
Ellen I Leonard, M.D.

LUBBOCK
Covenant Health System
Codirectors:
Bachar Al-Alami, M D, P.A.
Roger Wolcott, M.D.

MIDLAND
Midland Memorial Hospital
Director:
John W Foster Jr., M.D.

ROUND ROCK
Round Rock Medical Center
Director:
Adam D. Horvit, M D.

SAN ANGELO
Shannon Medical Center
Director:
Christopher W Vanderzant, D.O.

SAN ANTONIO
University of Texas Health Science Center
Director:
Carlayne Jackson, M.D.*

TYLER
University of Texas Health Center at Tyler
Codirectors:
Angelita D Tangco, M.D
Mark C. Race, M.D.

WACO
Providence Health Center
Director:
George Mark Schwartze, M.D

WICHITA FALLS
Clinics of North Texas
Director
Stephen Farmer, D.O

UTAH

SALT LAKE CITY
University of Utah Medical Center
Director:
Mark B. Bromberg, M D, Ph D*

VERMONT

BURLINGTON
Fletcher Allen Health Care Center
Director:
Rup Tandan, M D.

VIRGINIA

CHARLOTTESVILLE
Kluge Children's Rehabilitation Center
Director
Christine M. Houlihan, M D

University of Virginia Hospital
Codirectors:
Lawrence H Phillips II, M D.
Vern Charles Juel, M D.
Ted M. Burns, M.D.

NORFOLK
Sentara-Norfolk General Hospital
Director:
L. Matthew Frank, M D

RICHMOND
Children's Hospital
Director.
Eugenio A. Monasterio, M D

Medical College of Virginia
Codirectors:
Hernan T Gatuslao Jr, M D
Zakia D Bell, M D.

ROANOKE
Roanoke Neurological Center
Director:
Bashir K. Ahmad, M D

WASHINGTON

OLYMPIA
Providence/St. Peter's Hospital
Director
Greg Carter, M.D.

PASCO
Physicians Health Center
Director
Donald G Dicken, M D, PC

SEATTLE
Children's Hospital Medical Center
Director.
Kenneth Jaffe, M.D.

University of Washington Medical Center
Codirectors
George H Kraft, M D
Thomas Bird, M D.
Gregory Carter, M D*
Michael Weiss, M.D.*

SPOKANE
St. Luke's Rehabilitation Institute
Director
Vivian M Moise, M.D.

WEST VIRGINIA

CHARLESTON
Charleston Area Medical Center
Codirectors:
Kenneth C Wright, M D
Sasidharan Taravath, M.D.

MORGANTOWN
West Virginia University Hospital
Codirectors.
Margaret E Jaynes, M.D
Laurie Gutmann, M D.

WHEELING
Ohio Valley Medical Center
Codirectors
Srini Govindan, M D
Henry L. Kettler, M.D.

WISCONSIN

GREEN BAY
St. Vincent Hospital
Director.
Terence S. Edgar, M D.

MADISON
University of Wisconsin Hospitals and Clinics
Codirectors:
Benjamin R. Brooks, M D.*
Barend P. Lotz, M.D.
Andrew J Waclawik, M D

MARSHFIELD
Marshfield Clinic
Director:
Rodney Sorensen, D O.

MILWAUKEE
Children's Hospital of Wisconsin
Medical College of Wisconsin
Director
Richard D Jacobson, M D, Ph D

Froedtert Memorial Lutheran/Medical College of Wisconsin
Codirectors.
Wendy L. Peltier, M D
Alexandru C Barboi, M.D

Exhibit M
Form 990
Schedule A Part III
Line 2d

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
RELATED PARTY TRANSACTION
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

Stanley H. Appel, M.D. at Baylor College of Medicine serves as a member of the Association's Board of Directors. For the year ended March 31, 2005, Dr. Appel was awarded research grants in the amount of $110,000 for ALS research. He also was a recipient of an earmark gift in the amount of $22,973 for ALS research. By policy, Mr. Appel excuses himself for discussions and voting on consideration of his grant.

Exhibit N
Form 990
Part 1 Line 20

MUSCULAR DYSTROPHY ASSOCIATION, INC.
#13-1665552
OTHER CHANGES IN NET ASSETS OR FUND BALANCES
FOR THE FISCAL YEAR ENDED MARCH 31, 2005

Minimum Pension Liability	$	9,032,962
Net Unrealized Losses on Investments		3,507,631
	$	12,540,593

Form **8868**
(Rev December 2004)
Department of the Treasury
Internal Revenue Service

Application for Extension of Time To File an Exempt Organization Return

► File a separate application for each return

OMB No 1545-1709

- If you are filing for an **Automatic 3-Month Extension, complete only Part I** and check this box . . . . . ► ☑
- If you are filing for an **Additional (not automatic) 3-Month Extension, complete only Part II** (on page 2 of this form).

Do not complete Part II unless you have already been granted an automatic 3-month extension on a previously filed Form 8868.

Part I **Automatic 3-Month Extension of Time**—Only submit original (no copies needed)

Form 990-T corporations requesting an automatic 6-month extension—check this box and complete Part I only . . ► ☐

All other corporations (including Form 990-C filers) must use Form 7004 to request an extension of time to file income tax returns. Partnerships, REMICs, and trusts must use Form 8736 to request an extension of time to file Form 1065, 1066, or 1041.

Electronic Filing (e-file). Form 8868 can be filed electronically if you want a 3-month automatic extension of time to file one of the returns noted below (6 months for corporate Form 990-T filers). However, you cannot file it electronically if you want the additional (not automatic) 3-month extension, instead you must submit the fully completed signed page 2 (Part II) of Form 8868. For more details on the electronic filing of this form, visit *www.irs.gov/efile*.

Type or print File by the due date for filing your return See instructions	Name of Exempt Organization	Employer identification number
	Muscular Dystrophy Association, Inc.	**13 : 1665552**
	Number, street, and room or suite no If a P.O. box, see instructions. **3300 East Sunrise Drive**	
	City, town or post office, state, and ZIP code For a foreign address, see instructions. **Tucson, Arizona 85718-3299**	

Check type of return to be filed (file a separate application for each return):

☑ Form 990	☐ Form 990-T (corporation)	☐ Form 4720
☐ Form 990-BL	☐ Form 990-T (sec. 401(a) or 408(a) trust)	☐ Form 5227
☐ Form 990-EZ	☐ Form 990-T (trust other than above)	☐ Form 6069
☐ Form 990-PF	☐ Form 1041-A	☐ Form 8870

- The books are in the care of ► **Daniel Bereck**

Telephone No. ► (**520**) **529-5200** FAX No. ► (**520**) **529-5404**

- If the organization does **not** have an office or place of business in the United States, check this box . . . . . ► ☐
- If this is for a **Group Return,** enter the organization's four digit Group Exemption Number (GEN) _____. If this is for the **whole** group, check this box ►☐. If it is for part of the group, check this box ► ☐ and attach a list with the names and EINs of all members the extension will cover.

1 I request an automatic 3-month (6-months for a **Form 990-T corporation**) extension of time until **November 15**, 20**05**, to file the exempt organization return for the organization named above. The extension is for the organization's return for.
► ☐ calendar year 20 ... or
► ☑ tax year beginning **April 1**, 20**04**, and ending **March 31**, 20**05**.

2 If this tax year is for less than 12 months, check reason: ☐ Initial return ☐ Final return ☐ Change in accounting period

3a If this application is for Form 990-BL, 990-PF, 990-T, 4720, or 6069, enter the tentative tax, less any nonrefundable credits. See instructions . . . . . $

b If this application is for Form 990-PF or 990-T, enter any refundable credits and estimated tax payments made. Include any prior year overpayment allowed as a credit . . . . . $

c **Balance Due.** Subtract line 3b from line 3a. Include your payment with this form, or, if required, deposit with FTD coupon or, if required, by using EFTPS (Electronic Federal Tax Payment System). See instructions . . . . . $

Caution. If you are going to make an electronic fund withdrawal with this Form 8868, see Form 8453-EO and Form 8879-EO for payment instructions.